Epidemiologic Study of Gastric Cancer in Iran: A Systematic Review

This article was published in the following Dove Press journal:
Clinical and Experimental Gastroenterology

Khadijeh Kalan Farmanfarma¹
Neda Mahdavi²
Soheil Hassanipour³
Hamid Salehiniya⁴

¹Department of Epidemiology, Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, Iran; ²Department of Biostatistics and Epidemiology, School of Health, Non-Communicable Diseases Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran; ³Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran; ⁴Social Determinants of Health Research Center, Birjand University of Medical Sciences, Birjand, Iran

Background: Gastric cancer (GC) is one of the most common cancers in Iran. Knowledge of the epidemiology of the disease is essential in planning for prevention. So this study aimed to investigate the epidemiological aspects of gastric cancer including prevalence, incidence, mortality, and risk factors of Iran.

Methods: This systematic review study was based on articles published in both English and Persian languages during the years of 1970–2020 in international databases (PubMed, Web of Science, Scopus) and national databases (including SID, Magiran, and IranDoc). Papers related to epidemiological aspects of the disease including mortality, prevalence, incidence, and risk entered the final review.

Results: According to the studies, the minimum and maximum prevalence of gastric cancer in northwestern Iran (Ardabil) is between 0.2 and 100 per 100,000. Also, the death rate per 100,000 people ranged from 10.6 to 15.72 and the ASMR ranged from 4.2 to 32.2%. On the other hand, the incidence of GC was higher in men than in women (74.9 vs 4.6%). The GC risk ratio was 8-times higher in the elderly than in the other age groups (HR=8.0, 2.7–23.5). The incidence of gastric cancer in patients with *H. pylori* infection was 18-times and that of smokers 2-times higher than other populations. Low level of economic situation and food insecurity increased the odds of GC by 2.42- and 2.57-times, respectively. It should be noted that there was a direct relationship between consumption of processed red meat, dairy products, fruit juice, smoked and salty fish and legumes, strong and hot tea, and consumption of salt and gastric cancer incidence. There was also an inverse relationship between citrus consumption, fresh fruit, garlic, and gastric cancer. In addition, the mRNA genes are the most GC-related genes.

Conclusion: Given the high incidence of GC in Iran, changing lifestyle and decreasing consumption of preservatives in food, increasing consumption of fruits and vegetables, and improving the lifestyle can be effective in reducing the incidence of this disease.

Keywords: epidemiology, gastric cancer, Iran, risk factor, systematic review

Introduction

Gastric cancer is one of the most common cancers in the world,¹ with the highest incidence in the countries of Western Asia, Latin America, and the former Soviet Union. The incidence among Japanese, Korean, and Iranian males were 66.7, 64.6, and 30.4%, respectively.²

Gastric cancer, with an annual incidence of 7300, is one of the five most common cancers in Iranian men and women.³ It is the first cause of cancer death in both genders in Iran as most patients are diagnosed at advanced stages of the disease.⁴ Also, the 5-year survival rate in Iran is estimated to be less than 25%.⁵

Correspondence: Hamid Salehiniya
Tel +98 9357750428
Email alesaleh70@yahoo.com

Helicobacter pylori, genetics, gastric ulcer, cigarettes, alcohol, chemical exposure, reflux, chronic anemia, gastric surgery, obesity, radiation, Epstein-Barr virus, gender, race, ethnicity, economic-social status, Type A blood groups, and food play an important role in the risk of gastric cancer.⁶ Improving living standards and changing dietary habits as well as reducing *H. pylori* infection are very effective in reducing the incidence of gastric cancer.⁷ Understanding the epidemiologic status of the disease and associated risk factors are essential for planning to diminish the disease, so this study aimed to investigate the epidemiological aspects of gastric cancer including prevalence, incidence, mortality, and risk factors of Iran.

Materials and Methods

Eligibility Criteria

In this study, original articles in the Iranian population which are published in Persian and English language, and published in national and international journals during the years of 1970–2020 with accessible full text, were reviewed.

Information Sources

Articles were selected from international databases (PubMed, Web of Science, Scopus) and national databases (SID, Magiran, and IranDoc).

Study Selection

Papers related to epidemiological aspects of the disease including mortality, prevalence, incidence, risk factors and genetics were reviewed. The results of the studies were presented in separate tables including mortality, prevalence, incidence, and risk factors of genetics.

It should be noted that studies lacking necessary information and links to the topic under discussion were excluded from the study.

Data Collection Process

Abstract and full text of articles, independently, by two relevant researchers, reviewing and listing information prepared for this purpose, including: author's name, year of publication, place of study, gender, sample size, age incidence, prevalence, and factors. The hazards of the genes in the articles and other cases were recorded in separate tables.

In order to increase the accuracy and reliability of the information and to reduce possible bias, the second review was performed by a second researcher and then registered by both researchers.

Summary Measures

Articles related to incidence, mortality, prevalence, risk factors, and genetics were selected in the period of 1970 to 2020 and the results are presented in separate tables.

Synthesis of Results

A total of 3461 articles were initially reviewed. It should be noted that 68 articles were not accessible to the full text, 1823 were duplicate, 822 were fully studied, 593 were irrelevant, and finally 229 were entered (Figure 1).

Results

Incidence

The incidence of gastric cancer in Iran increases due to increasing health level, lifestyle, awareness of early symptoms, and early diagnosis.⁸ On the other hand, with growth of urbanization, the incidence and consequently the mortality rate will increase.⁹ One of the causes of the rising incidence of gastric cancer in Iran is related to the diagnosis of end stage (non-curable stage=end stage) disease.^{10,11}

Most patients are diagnosed in advanced stages and cannot be diagnosed at an early stage.¹² Studies in most parts of Iran indicate a high prevalence of this disease,¹³ with the provinces located in the north and northwest as high risk areas and those located in southwestern Iran as medium risk areas.¹⁴

Epidemiological studies in Iran show a higher incidence of this disease in men than in women (74.9 vs 4.6). On the other hand, the sudden decrease in the incidence of disease over the age of 80 indicates the limitation of healthcare in this age group in Iran (Table 1). Increasing trend of GC is observed in the majority of men in Tehran province and most women in East Azerbaijan, Markazi, Tehran, and Yazd provinces.¹⁵

Non-use of refrigerator in some parts of the country, incorrect food preservation methods, high prevalence of *H. pylori*, and consumption of salty and nitrogen-containing foods, drinking hot tea, smoking and drinking contaminated water, smoking, and opium are important causes of gastric cancer in Iran.^{16,17} In contrast, in the southern regions of Iran due to high consumption of dates as an antioxidant, the incidence of GC decreases.¹⁵

Mortality

In 2012, the rate of gastric cancer deaths in Iran was 11.4%, and it was reported as the second leading cause

Figure 1 Flowchart of the included eligible studies in systematic review.

of death from common cancers in Iran. In fact, 15.5% of all cancer deaths in Iran are attributable to gastric cancer.^{18,19} Currently, the highest mortality rate in Southwest and Central Asian countries is observable in Iran (19.9 per 100,000).²⁰

GC is one of the most important causes of cancer death in Iran²¹ which is due to individual or environmental factors, *H-Pylori* infection, and gastric atrophy in an Iranian population.²² It should be noted that the incidence of GC mortality has decreased over the last five decades worldwide.¹⁵ Thus, the number of deaths due to GC in Iranian military has been steady, which may be due to early diagnosis of this disease.²³ ASMR ranged from 4.2–32.2% (Table 2).

Prevalence

Gastric cancer is one of the most common cancers among Iranian men and women,¹² as it become the first common cancer among Iranian men.⁹ The higher prevalence of

males than females can be due to risky occupations such as agriculture, which may lead to exposure to nitrate-contaminated soil and chemical fertilizers as well as men's genetic susceptibility and, in turn, women's greater sensitivity to healthcare than men.^{24,25} The minimum and maximum prevalence of gastric cancer in the previous studies was observed in northwestern Iran (Ardabil) between 0.2–100%. Other provinces were within the mentioned range (Table 3).

Risk Factors

H.pylori

In Iran, more than 80% of the population over 40 years have a history of *H. pylori* infection.^{26,27} *H. pylori* is the most prominent risk factor for gastric cancer.²⁸ Age of infection seems to be very low in Iran. According to a study in southern Iran, 89% of 9-month-old children and 98% of 2-year-olds have been infected.²⁹ Studies have shown that *H. pylori* infection has an 18% higher

Table 1 Incidence Rate of Gastric Cancer in Iran

First Author/ Year (Reference Number)	Province(District)	Type of Study	Sample-Size	ASR ^a
Ahmadi (2018) ⁷²	Chaharmahal and Bakhtiari	Retrospective	2918	
Aghaei (2013) ⁷³	Tehran	-	4463	-
Almasi (2015) ⁷⁴	All of Iran	Cross-sectional	35,171	7.1 15.1
Almasi (2016) ⁷⁵	All of Iran	Cross-sectional	9660	15.2
Amani (2015) ⁷⁶	Ardabil	Cross-sectional	1056	
Amoori (2014) ⁷⁷	Khuzestan	Retrospective	14,893	M=13.8 F= -
Amori (2017) ⁷⁸	All of Iran	Retrospective	301,055	M=15.02 F=7.05
Eishi (2016) ⁷⁹	Western Azerbaijan	Sectional & retrospective	2972	-
Babaei (2009) ⁸⁰	Ardabil	-	M=727 F=311	M=51.8 F=24.9
Babaei (2005) ⁸¹	Semnan		M=936 F=796	M=36.9 F=14.8
Behnampour (2014) ⁶⁵	Golestan	Case-control	M=107 F=49	13.93
Jenab (2019) ⁸²	All of Iran	Ecological	4484	15.93
Hassanzade (2011) ⁸³	Fars	-	M=46 F=31	M=9.99 F=4.66
Chamanpara (2015) ⁸⁴	Golestan		1087	0.8–1.2
Haghdost (2008) ⁸⁵	kerman	-	1112	
Haghigh (1971) ⁸⁶	Fars		182	
Khodadost (2015) ⁸⁷	Ardabil		857	
Sadjadi (2005) ⁸⁸	Golestan, Mazandaran, Kerman, Ardabil	-	51,000	M=26.1 F=11.1
Khazaei (2018) ⁸⁹	All of Iran	-	M=5398 F=2353	M=19.1 F=10
Masoompour (2016) ⁹⁰	Fars		-	M=5.56 F=11.21
Masoompour (2011) ⁹¹	Fars	-	M=597 F=273	M=9.2 F=4.4
Kavousi (2015) ⁹³	All of Iran	Ecologic	M=20,882 F=8592	

(Continued)

Table 1 (Continued).

First Author/ Year (Reference Number)	Province(District)	Type of Study	Sample-Size	ASR ^a
Moradpour (2013) ⁹⁴	Isfahan	-	2001: Male=190 Female=104	2001: Male=9.9 Female=5.6
			2010: Male=272 Female=162	2010: Male=12.8 Female=7.9
			2015: Male=390 Female=250	2015: Male=14.7 Female=9.5
Khazaei (2016) ⁸	All of Iran	Ecological	951,594	
Fateh (2013) ⁹⁵	Semnan	-	2240	15.52
Fararouei (2015) ⁹⁶	Kohgiluyeh and Boyer-Ahmad	Cohort	106	11.08
Keyghobadi (2015) ⁹⁷	Kerman	Cross-sectional	Male: 2004=671	Male: 2004=74.93
			2005=691	2005=71.43
			2006=915	2006=85.85
			2007=837	2007=79.2
			2008=1070	2008=104.22
			2009=1609	2009=131.61
			Female: 2004=572	Female: 2004=75.69
			2005=554	2005=61.79
			2006=765	2006=82.72
			2007=727	2007=78.88
			2008=851	2008=91.94
			2009=1333	2009=128.26
Faramarzi (2013) ⁹⁸	fars	Cross-sectional	Male=1652	Male=74.9
			Female=1072	Female=49.8
Mashhadi (2010) ⁹⁹	Sistan & Blouchestan	-	100	22%
Yasemi (2015) ¹⁴	ILAM	Retrospective cross-sectional	307	
Mohebbi (2011) ¹⁰⁰	Mazandaran	ecologic	2665	Male=Ardabil=49.1
Yavari (2006) ¹⁰¹	Ardabil and Kerman Iranian immigrants (BC Iranians)	-	-	Kerman=10.2
				Female=Ardabil=25.4
				Kerman=5.1
				BC Iranians=6.5

(Continued)

Table 1 (Continued).

First Author/ Year (Reference Number)	Province(District)	Type of Study	Sample-Size	ASR ^a
Vakili (2014) ¹⁰²	Yazd	Cross-sectional	4631	Female: 2005=3.3
				2006=4.8
				2007=4.2
				2008=4.6
				2009=4.3
				Male: 2005=7.2
				2006=8.2
				2007=7.5
				2008=9.4
				2009=8.5
Darabi (2016) ¹⁰³	All of Iran	-	Male: 2001=1105	Male: 2001=4.18
			2010=5192	2010=17.06
			Female: 2001=484	Female: 2001=2.41
			2010=2238	2010=8.85
Salehiniya (2016) ¹⁷	Gilan, Mazandran and Golstan	Cross-sectional	Mazandran=2382	
			Gilan=1824	
			Golestan=709	
Talaiezhadeh (2013) ¹⁰⁴	Khuzestan	Retrospective	Male=667 Female=322	Male=7.17 Female=2.34
Mohagheghi (2009) ³¹	Tehran	-	Male=2119 Female=1033	Male=19.7 Female=10.0
Norouzinia (2012) ¹⁰⁵	Tehran, Khorasan, Lorestan, Mazandran, Khuzestan, East Azarbaijan, Kurdistan, and Sistan and Baluchesta	Retrospective	140	Lorestan=10.24
				Tehran=5.01
				Tabriz=2.21
				Zahedan=2.31
				Sanandaj=7.07
				Sari=4.23
				Ahvaz=2.3
				Mashhad=4.48
Askarian (2014) ¹⁰⁶	Fars	-	1171	85.04
Sadjadi (2014) ¹⁶	Ardabil	Cohort	928	
Norouzirad (2018) ¹⁰⁷	khuzestan	Cross-sectional		M=10.88 F=3.29

(Continued)

Table I (Continued).

First Author/ Year (Reference Number)	Province(District)	Type of Study	Sample-Size	ASR ^a
Mohammadian (2016) ¹³	Sistan and Baluchestan	-	255	Male: 2004=0–24 years=0
				25–29 years=1.06
				30–34 years=0
				35–39 years=1.48
				40–44 years=0
				45–49 years=2.0
				50–54 years=3.39
				55–59 years=18.42
				60–64 years=22.61
				65–69 years=11.19
				70–74 years=10.83
				75–79 years=7.47
				>80 years=0
				Female: 2004=0–29 years=0
				30–34 years=1.30
				35–39 years=1.53
				40–44 years=1.69
				45–49 years=6.88
				50–54 years=7.73
				55–74 years=0
				75–79 years=10.46
				>80 years=0
				2005: male=0–24 years=0
				25–29 years=0.97
				30–34 years=1.19
				35–39 years=4.08
				40–44 years=3.17
				45–49 years=0
				50–54 years=6.24

(Continued)

Table I (Continued).

First Author/ Year (Reference Number)	Province(District)	Type of Study	Sample-Size	ASR ^a
				55–59 years=20.33
				60–64 years=23.76
				65–69 years=10.29
				70–74 years=34.87
				75–79 years=20.63
				80–84 years=40.54
				>85 years=54.38
				Female: 2005=0-19 years=0
				20–24 years=0.82
				25–29 years=1.08
				30–34 years=0
				35–39 years=1.41
				40–44 years=0
				45–49 years=2.11
				50–54 years=2.37
				55–59 years=0
				60–64 years=4.44
				65–69 years=14.77
				70–74 years=5.66
				75–79 years=9.62
				>80 years=0
				2006: 0-24 years=0
				25–29 years=0.97
				30–39 years=0
				40–44 years=12.69
				45–49 years=3.68
				50–54 years=9.36
				55–59 years=6.78
				60–64 years=14.85

(Continued)

Table 1 (Continued).

First Author/ Year (Reference Number)	Province(District)	Type of Study	Sample-Size	ASR ^a
				65–69 years=17.15
				70–74 years=29.89
				80–84 years=40.54
				>85 years=0
				Female: 2006=0.14=0
				15–19 years=0.61
				20–24 years=0
				25–29 years=1.08
				30–34 years=0
				35–39 years=2.82
				40–44 years=3.11
				45–49 years=6.3
				50–54 years=4.74
				55–59 years=3.56
				60–64 years=13.33
				65–69 years=0
				70–74 years=11.32
				75–79 years=19.25
				80–84 years=0
				>85 years=29.52
				Male: 2007=0–9=0
				10–14 years=0.58
				15–19 years=0
				20–24 years=0.87
				25–39 years=0
				40–44 years=4.76
				45–49 years=3.68
				50–54 years=15.60
				55–59 years=13.55

(Continued)

Table 1 (Continued).

First Author/ Year (Reference Number)	Province(District)	Type of Study	Sample-Size	ASR ^a
				60–64 years=8.91
				70–74 years=39.85
				75–79 years=13.75
				80–84 years=60.80
				>85 years=0
				Female: 2007=0–44 years=0
				45–49 years=4.22
				50–54 years=2.37
				55–59 years=3.56
				60–64 years=0
				65–69 years=4.92
				70–74 years=5.66
				75–79 years=19.25
				80–>85 years=0
Najafi (2011) ¹⁰⁸	Kermanshah	-		1993=10.6
				1994=13.8
				1995=8.3
				1996=15.8
				1997=15.5
				1998=5.1
				1999=6.7
				2000=8.7
				2001=7.3
				2002=6.7
				2003=8.5
				2004=10.0
				2005=8.7
				2006=9.1
				2007=9.1

(Continued)

Table 1 (Continued).

First Author/ Year (Reference Number)	Province(District)	Type of Study	Sample-Size	ASR ^a
Mousavi (2009) ¹⁰⁹	All of Iran	-	2003–2004: Male=3088 Female=1166	2003–2004: Male=11.37 Female=5.20
			2004–2005: Male=3770 Female=1439	2004–2005: Male=13.74 Female=6.42
				2005–2006: Male=15.21 Female=6.89
Enayatrad (2014) ¹¹⁰	All of Iran	-	Male: 2003=3088	Male: 2003=11.37
			2004=3770	2004=13.74
			2005=4212	2005=14.90
			2006=4299	2006=15.24
			2007=4485	2007=15.93
			2008=5398	2008=19.16
			2009=4891	2009=16.01
			Female: 2003=1166	Female: 2003=5.20
			2004=1440 2005=1624	2004=6.42 2005=6.74
			2006=167	2006=6.65
			2007=173	2007=7.38
			2008=2353	2008=10.0
			2009=1995	2009=7.78
Haidari (2012) ¹¹¹	All of Iran	Cross-sectional	21,348	2000=2.8 (2.7–2.9)
				2001=2.6 (2.5–2.7)
				2002=4.6 (4.4–4.7)
				2003=7.1 (6.9–7.4)
				2004=7.9(7.7–8.1)
				2005=9.1(8.8–9.3)
Hosseintabar Marzoni (2015) ¹¹²	Golestan	-	1122	
Rastaghi, Tohid (2019) ¹⁵	All of Iran	Cross-sectional ecological	M=26,041 F=10,756	

Abbreviation: ASR, age standardized rate.

Table 2 The Death Rate of Gastric Cancer in Iran

First Author/ Year (Reference Number)	Province (District)	Type of Study	Sex	Sample-Size	Age- Standardized Mortality Rate per 100,000 (ASMR)	Death Number and Percent	Death per 100,000 People	RR (Relative Risk)	Cumulative Risk	Annual Mortality Rate/ 100,000
Ahmadipناه (2019) ¹³	All provinces in Iran except for Tehran	Ecological study	MF	395,002	-	-	-	RR>1.75		
Aghamohammadl (2017) ¹⁴	All provinces in Iran except for Tehran for 2006 & 2011 Isfahan & Tehran For 2007 & 2011	-	MF	2006– 2011=1,172,278	-	-	Ministry of Health And Medical Education: 1385=12.20 1386=11.75 1387=11.31 1388=11.18 1389=11.06 1390=10.17 United Nations: 1385=15.05 1386=15.72 1387=15.47 1388=15.35 1389=14.80 1390=13.56	-		
Almasi (2016) ⁷⁵	All of Iran	Cross- sectional	MF	8247	12.9				1.44	
Amoori (2016) ¹⁵	All of Iran	cross- sectional	MF	34,950	-	-	2006=11.20 2007=11.75 2008=11.31 2009=11.17 2010=11.06			
Babaei (2009) ⁸⁰	Ardabil	-	MF	M=465 F=206	M=32.2 F=16.3					
Pourhoseingholi (2013) ¹²	All of Iran	-	MF							1995=1.68 1996=3.04 1997=3.38 1998=2.29 1999=5.70 2000=6.04 2001=6.47 2002=9.86 2003=9.67 2004=8.78
Hassan Zade (2011) ⁸³	Fars	-	MF	M=46 F=31	M=11.54 F=4.21					

(Continued)

Table 2 (Continued).

First Author/ Year (Reference Number)	Province (District)	Type of Study	Sex	Sample-Size	Age- Standardized Mortality Rate per 100,000 (ASMR)	Death Number and Percent	Death per 100,000 People	RR (Relative Risk)	Cumulative Risk	Annual Mortality Rate/ 100,000
Khorasani (2015) ¹¹⁶	All of Iran	-	MF	M=5665 F=2582	-	M=18.8% F=11.11%				
Khazaei (2016) ⁸	All of Iran	Ecological	MF	723,073			10.2			
Moradpour (2013) ⁹⁴	Isfahan	-	MF	2001: M=116 F=68 2010: M=183 F=97 2015: M=283 F=166	2001: M=7.9 f=4.2 2010: M=9.3 F=5.2 2015: M=10.6 F=6.3					
Sadjadi (2005) ⁸⁸	Golestan, Mazandaran, Kerman, Ardabil	-	MF	7843		6638				
Mousavi (2009) ¹⁰⁹	All of iran	-	MF				12.0			
Nalini (2018) ¹¹⁷	Golestan	Cohort	MF	432		1.39%				
Mohammadi (2017) ¹¹⁸	All of Iran	Cross- sectional	MF	514,550	M: 2006=16.7 2011=12.5 F: 2006=9.0 2011=6.9					

Note: Malekzadeh (2013),¹¹⁹ cox hazard ratio =1.19.

chance of developing gastric cancer than those without the above-mentioned infection (OR=18.58; CI=1.63–221.520)

Cigarette Smoking and Alcohol

Studies show a 25.4% prevalence of smoking among Iranian adults. High smoking in Iran requires special attention as a risk factor for gastric cancer.²⁰ Furthermore, the prevalence of gastric cancer is directly related to the frequency of smoking.^{9,30}

Some surveys in Iran reveal increasing prevalence of cigarette smoking at an early age and subsequently, rising trend of smoking-related cancers is similar to GC.³¹ According to studies, smoking has a 2-fold chance of developing gastric cancer (OR=2.07; 1.14–3.75) (Table 4).

Opium has traditionally been used in many Southeast Asian countries, especially Iran.³² It is noteworthy that tobacco use in the north and south of Iran is higher than in other parts of Iran.^{33,34} According to some investigations in Iran, the chance of gastric cancer in smokers,

especially opium consumers, is 3-times higher than those who did not consume (OR=3.0; 1.6–5.6) (Table 4). Because of the risk of hookah, especially for cancer, being less well known and the perception that tobacco is safer than cigarette smoking, the filtration of tobacco in water and the lower cost of hookah than smoking, the tendency for hookah smoking in Iran is increasing.³⁵ Studies show gastric cancer patients are 14% more likely to develop gastric cancer than others (OR=1.14; 0.29–4.42).

In the studies, alcohol consumption increased (OR=2.03; 0.44–9.31) times the chance of developing gastric cancer (Table 4). It should be noted that, due to the legal prohibition of alcohol consumption in Iran, under-reporting may be found in the studied investigations (Table 4).

Low Economic Level and Food Insecurity

In a survey in Iran, farmers and ranchers are considered to be high risk occupations in the prevention of gastric cancer. Findings suggest that gastric cancer is more common

Table 3 The Prevalence Rate Of Gastric Cancer In Iran

First Author/ Year (Reference Number)	Province (District)	Sample-Size	Sex	Prevalence
Ostadrahimi (2017) ¹²⁰	East-Azerbaijan	111	MF	36.9%
Islami (2004) ¹²¹	Golestan	116	M	Gastric cardia adenocarcinoma=16% Gastric noncardia adenocarcinoma=16%
Eishi (2016) ⁷⁹	Western Azerbaijan	2972	MF	9.7%
Almasi (2015) ⁷⁴	All of Iran	35,171	MF	Male: Adenocarcinoma, Nos: 2003=68.39 2004=68.59 2005=65.17 2006=61.60 2007=59.30 2008=61.54
				Signet Ring Cell Carcinoma: 2003=9.42 2004=9.63 2005=9.90 2006=10.26 2007=11.95 2008=9.73
				Adenocarcinoma, Intestinaltype: 2003=6.80 2004=8.51 2005=10.83 2006=12.82 2007=13.94 2008=10.58
				Carcinoma, Diffuse Type: 2003=2.91 2004=3.37 2005=3.96 2006=4.07 2007=3.77 2008=4.87
				Carcinoma, Nos: 2003=2.75 2004=10.9 2005=0.28 2006=1.88 2007=0.91 2008=0.74
				Mucinous adenocarcinoma: 2003=1.91 2004=1.64 2005=2.11 2006=1.88 2007=1.87 2008=1.50 Mucin-Producing Adenocarcinoma: 2003=2.17 2004=1.86 2005=2.04 2006=1.63 2007=1.56 2008=1.33
				F: Adenocarcinoma, Nos: =62.61 2004=65.60 2005=60.84 2006=55.33 2007=56.08 2008=58.90
				Signet Ring Cell Carcinoma: 2003=11.75 2004=12.44 2005=13.67 2006=13.60 2007=14.01 2008=12.07
				Adenocarcinoma, Intestinaltype: 2003=6.69 2004=6.46 2005=8.93 2006=12.98 2007=11.76 2008=9.14 Carcinoma, Diffuse Type: 2003=4.12 2004=3.75 2005=4.0 2006=5.61 2007=5.71 2008=5.10 Carcinoma, Nos: 2003=3.00 2004=1.46 2005=0.37 2006=1.81 2007=1.38 2008=0.72 Mucinous Adenocarcinoma:2003=1.72 2004=1.95 2005=2.59 2006=2.43 2007=1.67 2008=1.57 Mucin-Producing Adenocarcinoma: 2003=2.57 2004=1.74 2005=1.42 2006=1.37 2007=1.79 2008=1.23

(Continued)

Table 3 (Continued).

First Author/ Year (Reference Number)	Province (District)	Sample-Size	Sex	Prevalence
Amani (2015) ²⁰	Ardabil	1056	MF	Male: Ardabi)=73.1% Bilesvar=62.5 Germi=65.7 Kousar=88.9 Khalkhal=74.7 Meshkinshahr=74.3 Naming=74.4 Nir=83.9 Parsabad=84.2 Sarein=100 Other=68.2 Female: Ardabil=26.9 Bilesvar=37.5 Germi=34.3 Kousar=11.1 Khalkhal=25.3 Meshkinshahr=25.7 Naming=16.1 Nir=16.1 Parsabad=15.8 Sarein=0 Other=31.8%
Barekat (1971) ¹²²	Fars	M=131 F=42	MF	M=6.59 F=3.26
Bashash (2011) ¹²³	Ardabil	261	MF	M=70.9% F=28.7%
Pourhoseingholi (2008) ¹²⁴	Tehran	2674	MF	34.5%
Tabrizchee (1998) ¹²⁵	Kerman	2881	MF	M=9.70% F=6.30%
Tavoli (2007) ¹²⁶	Tehran	142	MF	30%
Hajmanoochehri (2013) ¹²⁷	Tehran	729	MF	64.3
Yasemi (2015) ¹⁴	Ilam	307	MF	34.2%
Mohebbi (2008) ⁹²	Mazandaran	1663	MF	44.7%
Khademloo (2018) ¹²⁸	Mazandaran	1232		2008=20% 2009=23.8% 2010=20% 2011=19.5% 2012=16.7%
Tayebi (2012) ¹²⁹	Mazandaran	596	MF	4.1%
Nikfarjam (2014) ¹³⁰	Mashhad	495	MF	10.7%
Hashemi (2017) ¹³¹	Mashhad,	30	MF	Intestinal type =90% Diffuse type =10%
Yazdizadeh (2005) ¹³²	Shiraz and the Tehran	1516	MF	Tehran=4% Shiraz=4%
Mehrabian (2010) ¹³³	—	3439	MF	
Kadivar (2016) ¹³⁴	Tehran	147	MF	32.6%
Karami (2014) ¹³⁵	Khuzestan	273	MF	1.4%
Moradpour (2013) ⁹⁴	Isfahan	2001: male=366 Female=209	MF	
		2010: male=582 female=357		
		2015: male=852 female=559		
Keyghobadi (2015) ⁹⁷	Kerman	789	MF	7.45%

(Continued)

Table 3 (Continued).

First Author/ Year (Reference Number)	Province (District)	Sample-Size	Sex	Prevalence
Mehrabani (2013) ⁹	Fars	574	MF	<35age=8.9% 36–44=10.6% 45–54=20.7% 55–64=20.2% 65–75=27.7% >75=11.7%
Malekzadeh (2004) ²²	Ardabil	1011	MF	Erythema=68.1% Erosion=10.6 Friability=0.3 Nodularity=4.7 Polyp=0.9 Ulcer gastric=3.0 Ulcer (duodenal)=1.9 Atrophic mucosa=0.2 Raised/thickened area=0.3

in underclass and lower socioeconomic groups.^{20,36} Increasing food insecurity in developing countries like Iran is due to lower economic levels and rising food costs. As the prevalence of food insecurity in Iran is estimated to be around 50%,³⁷ it is important to note that food insecurity is associated with low economic levels.³⁸ Because of the fact that income is an important factor to access adequate food in the community, people with higher economic status can have more choice in their diet.³⁹ For this reason, Iranian policymakers have emphasized the need to improve the economic status by the resistance economy.⁴⁰ Based on studies of low levels of economic and food insecurity, the odds of developing gastric cancer by 2.42- and 2.57-times is increasing, respectively (Table 4).

Family History and Blood Type A+

Family history is an important predictor of gastric cancer. Families with a history of gastric cancer have unique clinical manifestations.⁴¹ Disease among young people of Iranian families with gastric cancer emphasize the role of family history in disease.⁴² At the same time, family members experience similar environmental and lifestyle conditions. Family history of gastric cancer may not necessarily be related to genetic effects,⁴³ because environmental factors such as *H. pylori* infection play a more important role than genetic effects.⁴⁴ In the studied investigation, family history increased 2.12-times the chance of developing gastric cancer (Table 4). According to the studies, the prevalence of blood type A in an Iranian population is 30.25%.^{27,45} In this survey, blood group A+ was 18.8% (Table 4).

Epstein-Barr Virus (EBV) and HTLV-I

EBV prevalence in gastric cancer patients ranged from 6.25–6.6% (Table 4). Studies in Iran show low prevalence of EBV among GC patients.⁴⁶ This is estimated to be between 3–6.66%.⁴⁷ The differences in EBV abundance reflect socio-economic, health and cultural differences in individuals,⁴⁸ hence the relationship between incidence of GC and EBV in different regions may reflect epidemiological and clinical-pathological factors, dietary habits and, ultimately, genetic differences.⁴⁹ Epidemiological studies indicate HTLV-1 is endemic in some part of Iran such as Khorasan, where HTLV are reported as around 0.77–1.7% in blood donors of different regions.⁵⁰ The prevalence of blood group A was 18.8% (Table 4).

Diet

Studies have shown an inverse relationship between citrus fruits, fresh fruits, garlic consumption, and gastric cancer (Table 4). Fruits are rich in antioxidants due to their fiber, vitamins, and minerals that can prevent initiation or progression of cancer.^{51–53} Ascorbic acid and carotene in vegetables and fruits can eliminate nitrite.⁵⁴ Consuming some vegetables such as onions less than twice a week does not have any protective effect for this cancer (OR=1.28; 0.73–2.23). This is ambiguous, but may be related to the constituents of the soil (Table 4).

According to several studies, there is also a direct relationship between consumption of processed red meat, dairy products, fruit juice, smoked and salty fish, grain, strong and hot tea, and salt consumption, with a chance of incidence of gastric cancer (Table 4). Meats that are cooked at high temperatures such as frying and kebabs

Table 4 Risk Factors Associated with Gastric Cancer in Iran

First Author	Province	Sample-Size	Sex	Risk Factors	OR (Odds Ratio)
Islami (2004) ¹²¹	Golestan	Gastric cardia=42 Gastric noncardia=40	m	Alcohol	
				Smoking	
				Nass	
				Opium (new user)	
				Opium (old user)	
				Four risk factors (alcohol, cigarette, nass or opium)	
Etemadi (2014) ⁴²	Ardabil, Guilan, Mazandaran, Kordestan, and West Azarbaijan	197	M&F	Blood Type A ⁺	-
				A ⁻	
				B ⁺	
				O ⁺	
				O ⁻	
				AB ⁺	
				N/A	
				Alcoholconsumpti on(yes)	
				Alcoholconsumpti on(NO)	
				Alcoholconsumpti on	
				N/A	
				Smoking(heavy smoker)	
				Smoker	
				No smoking	
				N/A	
				Smoked food Low Moderate High N/A	
				Salty food Low Moderate High N/A	
				Nitrite Low Moderate High N/A	

(Continued)

Table 4 (Continued).

First Author	Province	Sample-Size	Sex	Risk Factors	OR (Odds Ratio)
				Hp Infection YES NO N/A	
Amoueian (2018) ⁴⁷	Khorasan Razavi	Case=56 Control=56	MF	Epstein-Barr virus (EBV)	-
Behnampour (2014) ⁶⁵	Golestan	M=107 F=49	MF	2.07 (1.14-3.75) Unwashed hands after defecation	History of smoking 2.61 (1.43-4.76)
				History of gastric cancer in first-degree relatives	2.46 (1.21-4.99)
				Other cancers (except for gastrointestinal cancer) in first-degree relatives	2.34 (0.92-5.96)
				Other cancers (except for gastrointestinal cancer) in second-degree relatives	4.38 (1.14-6.79)
				History of X-ray dye exposure	1.56 (0.85-2.85)
				History of CT scan encounter	2.32 (1.21-4.44)
				Charred flesh	1.65 (0.99-2.88)
				Irregular lunch-time	3.96 (0.96-6.32)
				Achalasia	76.97 (28.35-208.92)
				Helicobacter pylori	18.58 (1.63- 211.52)
				Gastric ulcer	2.71 (1.15-6.36)
				Low mobility and lack of appropriate activities	4.78 (1.34-16.99)
Boreiri (2013) ¹³⁶	Ardabil	1011	MF	Age (years) 51-60	
				2:61	
				Family history	
				Positive smoking	
				History Histological finding (Atrophic gastritis)	
				(Intestinal metaplasia)	
				Gastric ulcer	
Pakseresht (2011) ⁶⁰	Ardabil	Case=286 Control=304	MF	Total fat intake	1.33 (1.12-1.57)
				Carbohydrate (per 50 g)	1.00 (0.88- 1.13)
				Selenium (per 50 lg)	1.11 (0.80-1.54)
				Protein (per 10 g)	0.87 (0.76-0.99)
				Vitamin C (per 10 mg)	0.82 (0.76-0.87)
				Vitamin E (per 10 mg)	0.67 (0.44-1.03)
				0.37 (0.25-0.56)	Iron (per 5 mg)

(Continued)

Table 4 (Continued).

First Author	Province	Sample-Size	Sex	Risk Factors	OR (Odds Ratio)
				Zinc (per 5 mg)	0.47 (0.32–0.70)
				Energy (per 100 kcal)	0.99 (0.97–1.02)
Daneshi-Maskooni (2017) ³⁶	Tehran	Case=120 Control=120	MF	Food insecurity	2.57 (1.41– 4.66)
				Low economic level	2.42 (1.23– 4.76)
				Family history	1.98 (1.03– 3.80)
Safaei (2012) ⁴³	Tehran	746	MF	Family history	2.12 (1.72 – 3.28)
Ebrahim Tahaei (2011) ⁵⁰	Tehran	Case=201 Control=219	MF	HTLV-I antibodies	
Sadjadi (2014) ¹⁶	Ardebil	928	MF	Family history	
				Cigarette smoking	
				Hookah smoking	
				Opium use	
				Salt intake >6 gr/day	
Moghimi-Dehkordi (2011) ¹³⁷	Tehran	FDR=113 SDR=180	MF	Having a family history	-
Zendehdel (2010) ¹³⁸	Tehran	808	MF	Family history	
Faghihloo (2014) ⁴⁶	Tehran	90	MF	Epstein-Barr virus (EBV)	
Mashhadi (2009) ⁵⁶	Sistan & Blouchestan	100	MF	Family history smoking and tobacco <i>H. pylori</i> infection	
Naghizadeh Tahami (2014) ³²	Kerman	89	MF	Opium use Amount of daily use (>median)	3.0(1.6–5.6) 13.0 (4.2 –41.9)
				≤median	5.5 (1.0– 28.4)
				Duration (>median)	10.5 (2.4–46.1)
				≤median	6.8 (1.7–26.8)
				Cumulative use of Opium (>median)	9.2 (2.5–33.7)
				≤median	7.3 (1.2–43.0)
				Cigarette smoking Amount of daily use (>median)	1.4 (0.8–2.3) 1.9 (0.7–5.2)
				≤median	0.8 (0.2 –2.8)

(Continued)

Table 4 (Continued).

First Author	Province	Sample-Size	Sex	Risk Factors	OR (Odds Ratio)
				Duration (>median)	1.2 (0.3–4.2)
				≤median	1.5 (0.5–4.2)
				Cumulative use of smoking (>median)	2.4 (0.8–7.2)
				≤median	1.0 (0.2–3.8)
				Alcohol	1.2 (0.3–4.4)
Pourfarzi (2004) ⁵³	Ardabil	Case=217 Control=394	MF	Tobacco Cigarette	0.90 (0.54–1.49) 0.87 (0.52–1.46)
				Hubble-bubble	1.14 (0.29–4.42)
				Current smoker	0.71 (0.41–1.25)
				Ex-smoker	1.40 (0.63–3.12)
				Age at start (years)<20	0.54 (0.22–1.29)
				20–29	1.28 (0.65–2.54)
				>30	0.75 (0.36–1.54)
				Average cigarette daily >20	0.67 (0.35–1.30)
				<20	1.07 (0.57–1.99)
				Total smoking years→35	0.87 (0.45–1.70)
				21–35	1.11 (0.51–2.46)
				<20	0.61 (0.26–1.47)
				Non-filter	0.99 (0.23–4.31)
				Filtered	0.86 (0.51–1.47)
				Both equally	0.71 (0.15–3.41)
				Smoke inhalation (Deeply)	0.51 (0.27–0.99)
				Moderately or slightly	1.90 (0.91–4.01)
				Alcohol	2.03 (0.44–9.31)
				Agriculture	1.96 (0.95–4.01)
				Manufacturing	0.80 (0.25–2.58)
				Construction	1.78 (0.67–4.76)
				Wholesale and retailer	1.32 (0.39–4.49)
				Raw vegetables (3 times/week) (1–2 times/week)	2.08 (1.13–3.82) 1.56 (0.89–2.73)
				Yellow-orange vegetables (3 times/week) 1–2	1.78 (0.81–3.89) 2.07 (1.15–3.70)
				Garlic (3 times/week) (1–2 times/week)	0.35 (0.13–0.95) 0.48 (0.25–0.91)

(Continued)

Table 4 (Continued).

First Author	Province	Sample-Size	Sex	Risk Factors	OR (Odds Ratio)
				Onion ≥ once per day (3–4 times/week)	0.34 (0.19–0.62) 1.28 (0.73–2.23)
				Fresh fruits ≥ 3 times/week 1–2 times/week	0.89 (0.43–1.86) 0.44 (0.22–0.89)
				Citrus fruits (≥ 3 times/week) 1–2 times/week	0.31 (0.17–0.59) 0.18 (0.10–0.33)
				Juice ≥ once/week	1.29 (0.73–2.29)
				Red meat ≥ once/day 3–4/week	3.40 (1.79–6.46) 2.20 (1.26–3.85)
				Fresh fish ≥ once/week	0.37 (0.19–0.70)
				Chicken ≥ once/day 3–4/week	0.93 (0.39–2.20) 1.40 (0.80–2.42)
				Dairy products ≥ once/day 3–4/week	2.28 (1.23–4.22) 3.77 (1.92–7.42)
				Cheese ≥ once/day 3–4/week	1.16 (0.54–2.51) 1.00 (0.39–2.56)
				Smoked meats ≥ once/month	0.91 (0.40–2.09)
				Smoked fish ≥ once/month	1.09 (0.63–1.89)
				Processed meats ≥ once/month	1.14 (0.55–2.37)
				Salted fish ≥ once/month	1.08 (0.57–2.05)
				Pickled vegetables ≥ once/week	1.47 (0.84–2.58)
				Beans > once/week	1.04 (0.65–1.66)
				Sweets ≥ once/week	0.70 (0.38–1.29)
				Seeds ≥ once/month	0.96 (0.37–2.46)
				Salt preference	3.10 (1.88–5.10)
				Strength of tea	2.64 (1.45–4.80)
				Warmth of tea Hot	2.85 (1.65–4.91)

produce various types of carcinogens such as polycyclic aromatic hydrocarbons that cause gastric cancer.⁵⁶ Also, salt by stimulating and damaging gastric mucosal tissue is effective in the development of gastric cancer.⁵⁵ It should be noted that canned foods, spicy pickle, and animal

protein are the dominant food among Iranian populations.⁵⁶ Pickles are an important risk factor for gastric cancer due to their high salt and nitrate compounds. It should be noted that the ingredients of pickles vary from country to country due to the amount of vegetables, salt and acidity.⁵⁷

Table 5 Genes Associated with Gastric Cancer in Iran

First Author(Year) (Reference Number)	Gene
Kulsom Ahmadi (2017) ¹³⁹	DNMT3B -579 G>T
Shirin Azarbarzin (2017) ¹⁴⁰	miR-383
Shirin Azarbarzin (2016) ⁶⁷	miR-299-5p
Fatemeh Azarkhazin (2017) ¹⁴¹	<i>Casp8</i> and <i>Apaf1</i>
Ramin Azarhoush (2008) ¹⁴²	p53
Malek H. Asadi (2010) ¹⁴³	OCT4
Ahmad Ismaili (2015) ¹⁴⁴	IL-1B+3954
Saeed Mahboubi Aghdam (2014) ¹⁴⁵	oipA and iceA2
Hassan Akrami (2016) ¹⁴⁶	PI3K/Akt1 and p38MAPK
Sakineh Amoueiian (2015) ¹⁴⁷	CD56, CD68, CD117 and CD1a
Mohammad Amini (2019) ¹⁴⁸	GHSR DNA
Mostafa Iranpour (2019) ¹⁴⁹	<i>PI3KCA</i>
Nooshin Ayremlou (2015) ¹⁵⁰	miR-107
Ali Basi (2012) ¹⁵¹	HER2
Nader Bagheri (2013) ⁷¹	IL-18 mRNA
Vahid Bagheri (2019) ¹⁵²	mRNA
Nader Bagheri (2014) ¹⁵³	TLR-4
Nader Bagheri (2018) ¹⁵⁴	MMP-3 and MMP-9
Seyedeh Zahra Bakhti (2015) ¹⁵⁴	vacA 3'-end
Gholam Basati (2017) ¹⁵⁵	PPAR γ
Zeinab Basiri (2014) ¹⁵⁶	vacA d1
Ali Bahadori (2017) ¹⁵⁷	cagPAI and vacA
Ali Bahadori (2017) ¹⁵⁸	cagPAI and vacA
Bahari (2015) ¹⁵⁹	<i>MIR17HG</i>
Mohammadreza Beheshtizadeh (2017) ¹⁶⁰	<i>G3BP1</i> and <i>VEZT</i>
Shahab Bohlooli (2012) ¹⁶¹	KYSE30
Modjtaba Emadi Baygi (2012) ¹⁶²	<i>MTDH</i>
Sanaz Savabkar (2013) ¹⁶³	PD-1.5C/T (rs2227981, +7785)
Ghasem Janbabai (2015) ¹⁶⁴	<i>EGFR</i> , <i>ErbB2</i> and <i>MET</i>
Naser Jafargholizadeh (2017) ¹⁶⁵	<i>LC3</i> mRNA
Fereshteh Jafar (2008) ¹⁶⁶	vacA
Milad Javanbakht (2017) ¹⁶⁷	Oct-4 and MUC5AC
Fereshteh Jeivad (2012) ¹⁶⁸	tyrosine kinases
Mina Rezaee Cherati (2017) ¹⁶⁹	N58E59
Nasim Hafezi (2015) ¹⁷⁰	CD1d
Maryam Habibzadeh (2017) ¹⁷¹	TLR2-196 to -174 ins/del, Arg753Gln and Arg677Trp
Afshin Habibi (2015) ¹⁷²	CD34
Asghar Hosseinzadeh (2016) ¹⁷³	mRNA
N. R. Hussein (2010) ¹⁷⁴	dupA
Mohammad Reza Haghshenas (2009) ¹⁷⁵	(IL)-18
Khatoon Heidari (2017) ¹⁷⁶	<i>BabA2</i> , <i>Hpa</i>
Abdulkuddous Heydari-Mehrabadi (2018) ¹⁷⁷	<i>ASIC1</i> and <i>IL-6</i>
Fatemeh Khatami (2009) ¹⁷⁸	DNA methyltransferase I
Malihea Khaleghian (2015) ¹⁷⁹	C-MYC

(Continued)

Table 5 (Continued).

First Author(Year) (Reference Number)	Gene
Mitra Khalili (2015) ¹⁸⁰	miR-302, miR-145, SOX2, c-MYC, and P21
Mitra Khalili (2012) ¹⁸¹	Mir-302b
Maryam Daneshpour (2018) ¹⁸²	miR-106a and let-7a
Zohreh Salehi (2017) ¹⁸³	miRNAs
Sabahi (2010) ¹⁸⁴	<i>MDR1</i>
ahra Sedarat (2018) ¹⁸⁵	HopQ and SabA
Negar Souod (2013) ¹⁸⁶	cagA and vacA
Reza Safaralizadeh (2017) ¹⁸⁷	miR-216a and miR-217
Amin Talebi Bezmin Abadi (2011) ¹⁸⁸	<i>cagA</i> , <i>homA</i> , and <i>homB</i>
Amin Talebi Bezmin Abadi (2012) ¹⁸⁹	dupA
Amin Talebi Bezmin Abadi (2013) ¹⁹⁰	babA2
Saeid Abediankenari (2013) ¹⁹¹	EGFR
Esmat Abdi (2016) ¹⁹²	<i>babA2</i>
Rana Ezzeddini (2019) ¹⁹³	HIF-1 α and SREBP-1c
Hosein Effatpanah (2015) ¹⁹⁴	mir-21 and mir-221
Akbar Oghalaie (2016) ¹⁹⁵	HP0175
Hossein Dabiri (2017) ¹⁹⁶	vacA, cagA, cagE, oipA, iceA, babA2 and babB
Dardaei Alghalandis (2009) ¹⁹⁷	CEA
L. Dardaei (2011) ¹⁹⁸	CEA, CK20, TFF1 and MUC2
Mehdi Nikbakht Dastjerdi (2015) ¹⁹⁹	PLC/PRF5
Masoumeh Douraghi (2009) ²⁰⁰	vacA intermediate region cagA
Mahboobeh Razmkhah (2013) ²⁰¹	Anti-VacA
Masoumeh Rostami (2013) ²⁰²	SDF-1 α G801A
Ali Zare (2018) ²⁰³	H-ras
Ali Zare (2019) ²⁰⁴	miR-335, miR-124, miR-218 and miR-484
Seiran Zandi (2018) ²⁰⁵	miR-155-5p, miR-15a, miR-15b, and miR-186
Alireza Sadjadi (2013) ²⁰⁶	sirt2
Iraj Saadat (2001) ²⁰⁷	Serum Ghrelin
Azam Soleimani (2016) ²⁰⁸	GSTM1 and GSTT1
Sareh Sohrabi (2017) ²⁰⁹	miR-146a
Zahra Shahhoseini (2016) ²¹⁰	PTEN and CDKN1C/p57kip2
Samaneh Saberi (2012) ²¹¹	rs3130932
Zeinab Imani-Saber (2015) ²¹²	MTHFR C677T
Mohammad Masoudi (2009) ²¹³	PML
Mehdi Moghanibashi (2012) ²¹⁴	GSTM1 GSTO2 GSTT1
Meysam Moghbeli (2014) ²¹⁵	TFF1
Meysam Moghbeli (2019) ²¹⁶	hMLH1 and E-Cadherin
Sharareh Mokmeli (2016) ²¹⁷	ErbB1 and ErbB3
Zahra Malek-Hosseini (2015) ²¹⁸	ERCC1 C8092A
Maryam Mansoori (2015) ²¹⁹	IL-17A
	ABCB1

(Continued)

Table 5 (Continued).

First Author(Year) (Reference Number)	Gene
Seyedeh Habibeh Mirmajidi (2015) ²²⁰	<i>bcl2</i>
Rouhallah Najjar Sadeghi (2010) ²²¹	p53
Nowruz Najafzadeh (2015) ²²²	CD44
Seyedeh Elham Norollahi (2017) ²²³	WNT16
Mina Noormohammad (2016) ²²⁴	miR-222
Parvaneh Nikpour (2013) ²²⁵	MSI1
Parvaneh Nikpour (2014) ²²⁶	EYA1
Parvaneh Nikpour (2012) ²²⁷	ZFX
Mohammadreza Hajjari (2013) ²²⁸	SUZ12
Akbar Hedayatzadeh-Omran (2018) ²²⁹	P53
Abolghasem Hadinia (2007) ²³⁰	CTLA-4
Alireza Andalib (2013) ²³¹	anti-CCR5, anti-CXCR3, anti-CCR3 and anti-CCR4
Roya Kishani Farahani (2015) ²³²	IGF-I
Shirin Farjadian (2018) ²³³	HLA-G
Mahdie Hemati (2019) ²³⁴	Q192R and L55M
Sahar Honarmand-Jahromy (2015) ²³⁵	CagA EPIYA-C
Saeid Latifi-Navid (2013) ²³⁶	<i>vacA</i> d11-i1
Batool Mottaghi (2016) ²³⁶	<i>vacA</i> i
M. Motovali-Bashi (2015) ²³⁸	GT-repeat
Mojtahedi (2010) ²³⁹	p53
Maedeh Mohsenzadeh (2017) ²⁴⁰	RAR- β
Saghar Mohammadi (2017) ²⁴¹	SIRT3
Farideh Mohammadian (2016) ²⁴²	miR-18a, miR-21 and miR-221
Ashraf Mohamadkhani (2013) ²⁴³	Pepsinogen I, Pepsinogen II
Mohammadi (2015) ²⁴⁴	mRNA
Sayed-Hamid Madani (2015) ²⁴⁵	Her2-neu
Mohammad-Taher Moradi (2014) ²⁴⁶	p53,MDM2 SNP309
Mohammad-Taher Moradi (2015) ²⁴⁷	MnSOD Val-9Ala
Mohammad-Taher Moradi (2017) ²⁴⁸	GPX1 Pro198Leu
Hamid Ghaedi (2018) ²⁴⁹	miRNAs
Nasrin Gharaati-Far (2017) ¹⁶⁹	cationic lipids-mediated
Ghalandary M (2015) ²⁵⁰	CBX8
Sayed Mohammad Hossein Kashf (2015) ²⁵¹	IL-16
Dor Mohammad Kordi Tamandani (2015) ²⁵²	THR β
Elham Kalantari (2017) ²⁵³	Lgr5, DCLK1
Behnam Kamalidehghan (2006) ²⁵⁴	DmtDNA4977
Sholeh Kiani (2018) ²⁵⁵	CDX1 and CDX2

(Continued)

Table 5 (Continued).

First Author(Year) (Reference Number)	Gene
Pegah Larki (2018) ²⁵⁶	miR-21, miR-25, miR-93, and miR-106b
Rajeeh Mohammadian Amiri (2016) ²⁵⁷	NOD1 and NOD2
Seyedeh Habibeh Mirmajidi (2016) ²⁵⁸	Bcl2
Dor Mohammad Kordi-Tamandani (2014) ²⁵⁹	CTLA4

Studies have found a direct relationship between pickling and gastric cancer (Table 4) (OR=1.47; 0.84–2.58). Some surveys in Iran show low levels of selenium in gastric cancer patients.⁵⁸ The protective effect of selenium on cancer may be due to oxidative stress and DNA damage reduction, recovery of damaged DNA and apoptosis through the p53 tumor suppressor gene and induction of Phase II enzymes to detoxify carcinogenic cells.⁵⁹ Investigations show protein intake reduces the chance of gastric cancer (Table 4). High protein intake in a low-income Iranian rural population indicates a healthy lifestyle.⁶⁰ In addition, vitamins and minerals play an important role in preventing tumorigenesis. Iron or detoxification of oxidative free radicals can prevent DNA damage.⁶¹ Irregular food intake appears to cause gastric ulcers, which is not unexpected if gastric cancer is not treated in the long-term. The findings of the studies confirm the above (Table 4).

Age

GC is more common in people over 50 years of age⁶² and is more common in people between the ages of 70 and 80 years. The incidence of GC is also increasing at ages younger than 20 and 40 years.⁶³ In general, the highest incidence of GC is observed in the fifth and sixth decades of life, while the risk is reduced at ages younger than 44.¹⁵ According to some investigations, the risk ratio of GC in older people is eight times higher than in other age groups (HR=8.0; 2.7–23.5) (Table 4).

Achalasia

Achalasia is the most well-known esophageal motor disease. Many patients are treated for gastroesophageal reflux disease before detection of achalasia. Gastric adenocarcinoma is the most common malignancy causing pseudo-achalasia.⁶⁴ In

conducted surveys, patients with achalasia are 97% more likely to have GC other than those who do not have achalasia (Table 4).

Unwashed Hands After Defecation

Studies show that unwashed hands increase the odds of developing gastric cancer by 2.61-times (OR=2.61; 1.43–4.76) (Table 4). In recent decades, hand-eating has become very common in Iranian culture. Although it is good to wash your hands with water, it is not enough to eliminate contaminated microorganisms after excretion or exposure to toxic substances. Due to the frequent stool excretion and improper hand washing, the emergence of diseases associated with infected microorganisms (*H.pylori*) such as gastric ulcer or gastric cancer are expected.⁶⁵

History of X-Ray Dye Exposure and History of CT Scan Encounter

The use of modern technology such as computed tomography and radiography in the diagnosis of diseases has been widely observed in recent decades, irrespective of its side-effects and subsequent consequences.⁶⁶ According to the study, the odds of developing gastric cancer as a consequence of advanced technology are 91% and 39%, respectively (Table 4).

Genetics

mi-RNAs are a subset of non-coding RNAs that contain approximately 22 nucleotides. They also play important functions in various cellular processes including differentiation, proliferation, and apoptosis; furthermore, they play an important role in the development of some cancers, including GC.

Disruption in the regulation of genes such as miR-383 is associated with cancer.⁶⁷ It appears that more than one-third of the genes encoding human protein are controlled by mi-RNAs and have their genetic pathways exerting their effects.⁶⁸

In *H.pylori*-infected individuals, IL-18mRNA and IL-18 levels in gastric mucosa are increased,⁶⁹ so that IL-18 cytokines increase inflammatory conditions in chronic diseases with immune pleiotropic function,⁷⁰ and directly increase the IL-1, IL-6, and TNF- α cytokine from macrophages, promoting GC progression.⁷¹ According to research, mi-RNAs group genes are the most GC related genes (Table 5).

Conclusion

Given the high incidence of GC in Iran, changing lifestyle and decreasing consumption of preservatives in food, increasing consumption of fruits and vegetables, and improving lifestyle can be effective in reducing the incidence of this disease.

Disclosure

The authors report no conflicts of interest in this work.

References

- Farmanfarma KK, Mahdavi N, Mohammadian-Hafshejani A, Salehiny H. Testicular cancer in the world: an epidemiological review. *WCRJ*. 2018;5(4):e1180.
- Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends—an update. *Cancer Epidemiol Biomarkers Prev*. 2016;25(1):16–27. doi:10.1158/1055-9965.EPI-15-0578
- Dehdari T, Dehdari L, Jazayeri S. Diet-related stomach cancer behavior among Iranian college students: a text messaging intervention. *Asian Pac J Cancer Prev*. 2016;17(12):5165–5172.
- Akhavan A, Binesh F, Seifaddini A. Results of combination chemotherapy and radiation therapy in non-metastatic gastric cancer in Yazd-Iran. *Indian J Cancer*. 2015;52(1):40–43. doi:10.4103/0019-509X.175583
- Movahedi M, Afsharfard A, Moradi A, et al. Survival rate of gastric cancer in Iran. *J Res Med Sci*. 2009;14(6):367–373.
- Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. *Prz Gastroenterol*. 2019;14(1):26–38.
- Crew KD, Neugut AI. Epidemiology of gastric cancer. *World J Gastroenterol*. 2006;12(3):354–362. doi:10.3748/wjg.v12.i3.354
- Khazaei S, Rezaeian S, Soheylizad M, Khazaei S, Biderafsh A. Global incidence and mortality rates of stomach cancer and the human development index: an ecological study. *Asian Pac J Cancer Prev*. 2016;17(4):1701–1704. doi:10.7314/APJCP.2016.17.4.1701
- Mehrabani D, Hosseini SV, Rezaianzadeh A, Amini M, Mehrabani G, Tarrahi MJ. Prevalence of stomach cancer in Shiraz, Southern Iran. *J Res Med Sci*. 2013;18(4):335–337.
- Moghimidehkordi B, Safaee A, Zali MR. Survival rates and prognosis of gastric cancer using an actuarial life-table method. *Asian Pac J Cancer Prev*. 2008;9(2):317–321.
- Pourhoseingholi M, Moghimidehkordi B, Safaee A, Hajizadeh E, Solhpour A, Zali M. Prognostic factors in gastric cancer using log-normal censored regression model. *Indian J Med Res*. 2009;129(3):262–267.
- Pourhoseingholi MA, Fazeli Z, Ashtari S, Bavand-Pour FSF. Mortality trends of gastrointestinal cancers in Iranian population. *Gastroenterol Hepatol Bed Bench*. 2013;6(Suppl 1):S52.
- Mohammadian M, Mahdavi N, Salehiny H. Trend of incidence of gastric cancer in Sistan and Baluchistan province, Iran. *Asian J Pharm Clin Res*. 2016;9:230–233. doi:10.22159/ajpcr.2016.v9s3.14738
- Yasemi M, Ahmadi MRH, Peyman H, Yasemi MR, Khajavikhan J, Hemati K. A 7-years retrospective study of gastrointestinal cancers incidence in the Western Iran. *J Clin Diagn Res*. 2015;9(7):EC01.
- Rastaghi S, Jafari-Koshki T, Mahaki B, Bashiri Y, Mehrabani K, Soleimani A. Trends and risk factors of gastric cancer in Iran (2005–2010). *Int J Prev Med*. 2019;10:79. doi:10.4103/ijpvm.IJPVM_188_17

16. Sadjadi A, Derakhshan MH, Yazdanbod A, et al. Neglected role of hookah and opium in gastric carcinogenesis: a cohort study on risk factors and attributable fractions. *Int J Cancer Res.* 2014;134(1):181–188. doi:10.1002/ijc.28344
17. Salehiniya H, Dashdebi SG, Rafiemanesh H, Mohammadian-Hafshejani A, Enayatradd M. Time trend analysis of cancer incidence in caspian sea, 2004–2009: a population-based cancer registries study (northern Iran). *Caspian J Intern Med.* 2016;7(1):25–30.
18. Ferro A, Peleteiro B, Malvezzi M, et al. Worldwide trends in gastric cancer mortality (1980–2011), with predictions to 2015, and incidence by subtype. *Eur J Cancer.* 2014;50(7):1330–1344. doi:10.1016/j.ejca.2014.01.029
19. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. *Eur J Cancer.* 2013;49(6):1374–1403. doi:10.1016/j.ejca.2012.12.027
20. Amani F, Sadrkabir M, Sadeghieh Ahari S, et al. Epidemiology of Gastric Cancer in Northwest Iran: 2003–2011. *Middle East J Cancer.* 2015;6(3):189–193.
21. Ajdarkosh H, Sohrabi M, Moradniani M, et al. Prevalence of gastric precancerous lesions among chronic dyspeptic patients and related common risk factors. *Eur J Cancer Prev.* 2015;24(5):400–406. doi:10.1097/CEJ.0000000000000118
22. Malekzadeh R, Sotoudeh M, Derakhshan M, et al. Prevalence of gastric precancerous lesions in Ardabil, a high incidence province for gastric adenocarcinoma in the northwest of Iran. *J Clin Pathol.* 2004;57(1):37–42. doi:10.1136/jcp.57.1.37
23. Khoshdel AR, Ziaei M, Ghaffari HR, Azadi S, Alimohamadi Y. The prediction number of new cases and death of gastric cancer among iranian military community during 2007–2019. *Multidisciplinary Cancer Investigation.* 2018;2(2):14–19.
24. Rajaiefard A, Moghimi B, Tabatabaie SH, Safaie A, Tabeie SZ. Epidemiological and clinical features of gastric cancer: descriptive study of cancer registry cases of Fars province (2001–2006). *ISMJ.* 2011;14(2):114–121.
25. Rahimi F, Heidari M. Time trend analysis of stomach cancer incidence in the west of Iran. *Health and Development Journal.* 2012;1(2):100.
26. Zendehdel N, Nasser-Moghadam S, Malekzadeh R, et al. Helicobacter Pylori Reinfection Rate 3 Years After Successful Eradication. *J Gastroenterol Hepatol.* 2005;20(3):401–404.
27. Keramati MR, Sadeghian MH, Ayatollahi H, Badiie Z, Shakibayi H, Moghimi-Roudi A. Role of the Lewis and ABO blood group antigens in Helicobacter pylori Infection. *MJMS.* 2012;19(3):17.
28. Compare D, Rocco A, Nardone G. Risk factors in gastric cancer. *Eur Rev Med Pharmacol Sci.* 2010;14(4):302–308.
29. Alborzi A, Soltani J, Pourabbas B, et al. Prevalence of Helicobacter pylori infection in children (south of Iran). *Diagn Microbiol Infect Dis.* 2006;54(4):259–261. doi:10.1016/j.diagmicrobio.2005.10.012
30. Sung N, Choi K, Park E, et al. Smoking, alcohol and gastric cancer risk in Korean men: the National Health Insurance Corporation Study. *Br J Cancer.* 2007;97(5):700–704. doi:10.1038/sj.bjc.6603893
31. Mohagheghi S, Mousavi JS, Malekzadeh R, Parkin M. Cancer incidence in Tehran metropolis: the first report from the Tehran Population-based Cancer Registry, 1998–2001. *Arch Iran Med.* 2009;12(1):15–23.
32. Naghibzadeh TA, Khanjani N, Yazdi FV, Varzandeh M, HAGHDOOST AA. Opium as a risk factor for upper gastrointestinal cancers: a population-based case-control study in Iran. *Arch Iran Med.* 2014;17(1):2–6.
33. Ziaaddini H, Ziaaddini MR. The household survey of drug abuse in Kerman, Iran. *J Appl Sci.* 2005;5(2):380–382. doi:10.3923/jas.2005.380.382
34. Nakhaee N, Divsalar K, Meimandi MS, Dabiri S. Estimating the prevalence of opiates use by unlinked anonymous urine drug testing: a pilot study in Iran. *Subst Use Misuse.* 2008;43(3–4):513–520.
35. Mamtani R, Cheema S, Sheikh J, Al Mulla A, Lowenfels A, Maisonneuve P. Cancer risk in waterpipe smokers: a meta-analysis. *Int J Public Health.* 2017;62(1):73–83. doi:10.1007/s00038-016-0856-2
36. Daneshi-Maskooni M, Badri-Fariman M, Habibi N, et al. The relationship between food insecurity and esophageal and gastric cancers: a case-control study. *J Res Health Sci.* 2017;17(2):e00381.
37. Dorosty AR. Food insecurity and chronic diseases: the editorial. *Nutri Food Sci Res.* 2016;3(3):1–2. doi:10.18869/acadpub.nfsr.3.3.1
38. Kaiser LL, Townsend MS, Melgar-Quinonez HR, Fujii ML, Crawford PB. Choice of instrument influences relations between food insecurity and obesity in Latino women. *Am J Clin Nutr.* 2004;80(5):1372–1378. doi:10.1093/ajcn/80.5.1372
39. Rose D, Gundersen C, Oliveira V Socio-economic determinants of food insecurity in the United States: Evidence from the SIPP and CSFII datasets. 1998.
40. Poorolajal J. Resistance economy and new population policy in Iran. *JRHS.* 2017;17:1.
41. Lee W-J, Hong R-L, Lai I-R, Chen C-N, Lee P-H, Huang M-T. Clinicopathologic characteristics and prognoses of gastric cancer in patients with a positive familial history of cancer. *J Clin Gastroenterol.* 2003;36(1):30–33. doi:10.1097/00004836-200301000-00010
42. Etemadi M, Pourian M, Shakib A, Sabokbar T, Peyghanbari V, Shirkoobi R. A registry program for familial gastric cancer patients referred to Cancer Institute of Iran. *Asian Pac J Cancer Prev.* 2014;15(5):2141–2144. doi:10.7314/APJCP.2014.15.5.2141
43. Safaie A, Moghimi-Dehkordi B, Fatemi SR, Maserat E, Zali MR. Association of stomach cancer risk in individuals with family history of cancer. *Koomesh.* 2012;13(2):264–268.
44. Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. *Cancer Epidemiol.* 2009;467–477.
45. Keramati MR, Shakibaei H, Kheiyami MI, et al. Blood group antigens frequencies in the northeast of Iran. *Transfus Apher Sci.* 2011;45(2):133–136. doi:10.1016/j.transci.2011.07.006
46. Msc EF, Msc MRS. Prevalence and characteristics of Epstein-Barr virus-associated gastric cancer in Iran. *Arch Iran Med.* 2014;17(11):767.
47. Amoueian S, Attaranzadeh A, Gholamimollem Z, Sadeghi M, Hashemi S-M, Allahyari A. Epstein-Barr virus infection in adult patients with gastric cancer in Northeast of Iran. *Indian J Med Paediatr Oncol.* 2018;39(2):206–209. doi:10.4103/ijmpo.ijmpo_132_17
48. Arvin A, Campadelli-Fiume G, Mocarski E, et al. *Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis.* Cambridge University Press; 2007.
49. Camargo MC, Kim W-H, Chiaravalli AM, et al. Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis. *Gut.* 2014;63(2):236–243. doi:10.1136/gutjnl-2013-304531
50. Tahaei S, Mohebbi SR, Fatemi SR, et al. Low frequency of human T-cell lymphotropic virus 1 antibodies in Iranian gastric cancer patients in comparison to controls. *Asian Pac J Cancer Prev.* 2011;12:2447–2450.
51. Farmanfarma KK, Mohammadian M, Shahabinia Z, Hassanipour S, Salehiniya H. Brain cancer in the world: an epidemiological review. *W C R J.* 2019;6:5.
52. Farma KKF, Jalili Z, Zareban I, Pour MS. Effect of education on preventive behaviors of breast cancer in female teachers of guidance schools of Zahedan city based on health belief model. *J Educ Health Promot.* 2014;3:77.

53. Pourfarzi F, Whelan A, Kaldor J, Malekzadeh R. The role of diet and other environmental factors in the causation of gastric cancer in Iran—a population based study. *Int J Cancer*. 2009;125(8):1953–1960. doi:10.1002/ijc.24499
54. Drake IM, Davies MJ, Mapstone NP, et al. Ascorbic acid may protect against human gastric cancer by scavenging mucosal oxygen radicals. *Carcinogenesis*. 1996;17(3):559–562. doi:10.1093/carcin/17.3.559
55. Machida-Montani A, Sasazuki S, Inoue M, et al. Association of *Helicobacter pylori* infection and environmental factors in non-cardia gastric cancer in Japan. *Gastric Cancer*. 2004;7(1):46–53. doi:10.1007/s10120-004-0268-5
56. Mashhadi M, Nazem K, Abdollahinejad M. Gastric cancer in south East of Iran. *Int J Hematol Oncol Stem Cell Res*. 2009;3(4):38–42.
57. Takenaka S, Sera N, Tokiwa H, Hirohata I, Hirohata T. Identification of mutagens in Japanese pickles. *Mutation Research/Genetic Toxicology*. 1989;223(1):35–40. doi:10.1016/0165-1218(89)90060-8
58. Malekzadeh R, Derakhshan MH, Malekzadeh Z. Gastric cancer in Iran: epidemiology and risk factors. *Arch Iran Med*. 2009;12(6):576–583.
59. Wang C, Yuan Y, Hunt RH. The association between *Helicobacter pylori* infection and early gastric cancer: a meta-analysis. *Am J Gastroenterol*. 2007;102(8):1789. doi:10.1111/j.1572-0241.2007.01335.x
60. Pakseresht M, Forman D, Malekzadeh R, et al. Dietary habits and gastric cancer risk in north-west Iran. *Cancer Causes Control*. 2011;22(5):725–736. doi:10.1007/s10552-011-9744-5
61. Emerit J, Beaumont C, Trivin F. Iron metabolism, free radicals, and oxidative injury. *Biomedicine*. 2001;55(6):333–339.
62. Kavousi A, Bashiri Y, Mehrabi Y, Etemad K. Modeling high-risk areas for gastric cancer in men and women, 2005–2009. *J Isfahan Med Sch*. 2015;33(322):82–92.
63. Moghimi-Dehkordi B, Safaee A, Fatemi R, Ghiasi S, Zali MR. Impact of age on prognosis in Iranian patients with gastric carcinoma: review of 742 cases. *Asian Pac J Cancer Prev*. 2010;11(2):33–38.
64. Mikaeli J, Islami F, Mehrabi N, Elahi E, Malekzadeh R. Achalasia: a review of Western and Iranian Experiences and Studies. *GOVARESH*. 2010;15(2):116–128.
65. Behnampour N, Hajizadeh E, Zayeri F, Semnani S. Modeling of influential predictors of gastric cancer incidence rates in Golestan Province, North Iran. *Asian Pac J Cancer Prev*. 2014;15(3):1111–1117. doi:10.7314/APJCP.2014.15.3.1111
66. Yassibas E, Arslan P, Yalcin S. Evaluation of dietary and life-style habits of patients with gastric cancer: a case-control study in Turkey. *Asian Pac J Cancer Prev*. 2012;13(5):2291–2297. doi:10.7314/APJCP.2012.13.5.2291
67. Azarbarzin S, Feizi MAH, Safaralizadeh R, et al. The value of miR-299-5p in diagnosis and prognosis of intestinal-type gastric adenocarcinoma. *Biochem Genet*. 2016;54(4):413–420. doi:10.1007/s10528-016-9728-y
68. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? *Nat Rev Genet*. 2008;9(2):102–114. doi:10.1038/nrg2290
69. Day AS, Su B, Ceponis PJ, et al. *Helicobacter pylori* infection induces interleukin-18 production in gastric epithelial (AGS) cells. *Dig Dis Sci*. 2004;49(11–12):1830–1835. doi:10.1007/s10620-004-9579-y
70. Monteleone G, Trapasso F, Parrello T, et al. Bioactive IL-18 expression is up-regulated in Crohn's disease. *J Immunol*. 1999;163(1):143–147.
71. Bagheri N, Taghikhani A, Rahimian G, et al. Association between virulence factors of *helicobacter pylori* and gastric mucosal interleukin-18 mRNA expression in dyspeptic patients. *Microb Pathog*. 2013;65:7–13. doi:10.1016/j.micpath.2013.08.005
72. Ahmadi A, Salehi F. Evaluation of observed and the expected incidence of common cancers: an experience from Southwestern of Iran, 2010–2014. *J Res Med*. 2018;23:4.
73. Aghaei A, Ahmadi-Jouibari T, Baiki O, Mosavi-Jarrahi A. Estimation of the gastric cancer incidence in Tehran by two-source capture-recapture. *Asian Pac J Cancer Prev*. 2013;14(2):673–677. doi:10.7314/APJCP.2013.14.2.673
74. Almasi Z, Rafiemanesh H, Salehiniya H. Epidemiology characteristics and trends of incidence and morphology of stomach cancer in Iran. *Asian Pac J Cancer Prev*. 2015;16(7):2757–2761. doi:10.7314/APJCP.2015.16.7.2757
75. Almasi Z, Mohammadian-Hafshejani A, Salehiniya H. Incidence, mortality, and epidemiological aspects of cancers in Iran; differences with the world data. *Journal of BU ON*. 2016;21(4):994–1004.
76. Amani F, Ahari SS, Barzegari S, Hassanlouei B, Sadrkabar M, Farzaneh E. Analysis of relationships between altitude and distance from volcano with stomach Cancer incidence using a geographic information system. *Asian Pac J Cancer Prev*. 2015;16(16):6889–6894. doi:10.7314/APJCP.2015.16.16.6889
77. Amoori N, Mirzaei M, Cheraghi M. Incidence of cancers in Kuzestan province of iran: trend from 2004 to 2008. *Asian Pac J Cancer Prev*. 2014;15(19):8345–8349. doi:10.7314/APJCP.2014.15.19.8345
78. Amori N, Aghajani M, Asgarian F, Jazayeri M. Epidemiology and trend of common cancers in Iran (2004–2008). *Eur J Cancer Care*. 2017;26(5):e12449. doi:10.1111/ecc.12449
79. Eishi Oskuei A. Frequency of cancers and their demographic characteristics in patients referred to omid hospital of Urmia. *Int J Trop Med*. 2016;11(2):13–20.
80. Babaei M, Jaafarzadeh H, Sadjadi A, et al. Cancer incidence and mortality in Ardabil: report of an ongoing population-based cancer registry in Iran, 2004–2006. *Iran J Public Health*. 2009;35–45.
81. Babaei M, Mousavi S, Malek M, et al. Cancer occurrence in Semnan Province, Iran: results of a population-based cancer registry. *Asian Pac J Cancer Prev*. 2005;159–164.
82. Jenabi E, Saatchi M, Khazaei S, et al. National distribution of stomach cancer incidence in Iran: a population-based study. *Adv Hum Biol*. 2019;9(1):89–93. doi:10.4103/AIHB.AIHB_37_18
83. Hassanzade J. Incidence and mortality rate of common gastrointestinal cancers in south of Iran, a population based study. *Iran J Cancer Prev*. 2011;4(4):163.
84. Chamanpara P, Moghimbeigi A, Faradmal J, Poorolajal J. Joint disease mapping of two digestive cancers in Golestan Province, Iran using a shared component model. *Osong Public Health Res Perspect*. 2015;6(3):205–210. doi:10.1016/j.phrp.2015.02.002
85. Haghdoust -A-A, Hosseini H, Chamani G, et al. Rising incidence of adenocarcinoma of the esophagus in Kerman, Iran. *Arch Iran Med*. 2008;11(4):364–370.
86. Haghighi P, Nasr K. Gastrointestinal cancer in Iran. *J Chronic Dis*. 1971;24(10):625–633. doi:10.1016/0021-9681(71)90065-8
87. Khodadost M, Yavari P, Babaei M, et al. Estimating the completeness of gastric cancer registration in Ardabil/Iran by a capture-recapture method using population-based cancer registry data. *Asian Pac J Cancer Prev*. 2015;16(5):1981–1986. doi:10.7314/APJCP.2015.16.5.1981
88. Alireza S, Mehdi N, Ali M, Alireza M, Reza M, Parkin D. Cancer occurrence in Iran in 2002, an international perspective. *Asian Pac J Cancer Prev*. 2005;6(3):359.
89. Khazaei S, Mansori K, Ayubi E, et al. Gender-age disparity of cancers' incidence in Iran. *Acta Medica Iranica*. 2018;585–590.
90. Masoompour SM, Lankarani KB, Honarvar B, Tabatabaee SH, Moghadami M, Khosravizadegan Z. Changing epidemiology of common cancers in Southern Iran, 2007–2010: a cross sectional study. *PLoS One*. 2016;11(5):e0155669. doi:10.1371/journal.pone.0155669

91. Masoompour SM, Yarmohammadi H, Rezaianzadeh A, Lankarani KB. Cancer incidence in southern Iran, 1998–2002: results of population-based cancer registry. *Cancer Epidemiol.* 2011;35(5):e42–e7. doi:10.1016/j.canep.2011.05.018
92. MOHEBI M, NOURI JK, Mahmoudi M, et al. Time of occurrence and age distribution of digestive tract cancers in northern Iran. *Iranian J Publ Health.* 2008;37(1):8–19.
93. Kavousi A, Bashiri Y, Mehrabi Y, Etemad K, Teymourpour A. Identifying high-risk clusters of gastric cancer incidence in Iran, 2004–2009. *Asian Pac J Cancer Prev.* 2015;15(23):10335–10337. doi:10.7314/APJCP.2014.15.23.10335
94. Moradpour F, Fatemi Z. Estimation of the projections of the incidence rates, mortality and prevalence due to common cancer site in Isfahan, Iran. *Asian Pac J Cancer Prev.* 2013;14(6):3581–3585. doi:10.7314/APJCP.2013.14.6.3581
95. Fateh M, Emamian MH. Cancer incidence and trend analysis in Shahroud, Iran, 2000–2010. *Iran J Cancer Prev.* 2013;6(2):85.
96. Fararouei M, Parisai Z, Farahmand M, Haghighi RE, Toori MA. Cancer incidence appears to be rising in a small province in Islamic Republic of Iran: a population-based cohort study. *East Mediterr Health J.* 2015;21(5):319–325. doi:10.26719/2015.21.5.319
97. Keyghobadi N, Rafiemanesh H, Mohammadian-Hafshejani A, Enayatradd M, Salehiniya H. Epidemiology and trend of cancers in the province of Kerman: southeast of Iran. *Asian Pac J Cancer Prev.* 2015;16(4):1409–1413. doi:10.7314/APJCP.2015.16.4.1409
98. Faramarzi H, Bagheri P, Farahmandfar M, Lari MA. Cancer occurrence in the south of Iran based upon pathology reports (2001–2009). *J. Afr. Cancer.* 2013;5(3):137–143. doi:10.1007/s12558-013-0263-z
99. Mashhadi M, Zakeri Z, Abdollahinejad M. Cancer incidence in South East of Iran: results of a population-based cancer registry. *Shiraz E-Med J.* 2010;11(3):148–155.
100. Mohebbi M, Wolfe R, Jolley D, Forbes AB, Mahmoodi M, Burton RC. The spatial distribution of esophageal and gastric cancer in Caspian region of Iran: an ecological analysis of diet and socio-economic influences. *Int J Health Geogr.* 2011;10(1):13. doi:10.1186/1476-072X-10-13
101. Yavari P, Hislop TG, Bajdik C, et al. Comparison of cancer incidence in Iran and Iranian immigrants to British Columbia, Canada. *Asian Pac J Cancer Prev.* 2006;7(1):86.
102. Vakili M, Pirdehghan A, Adimi M, Sadeghian M, Akhondi M. Epidemiology and trend of cancer in Yazd, a central province of Iran, 2005–2009. *J Res Health Sci.* 2014;14(3):210–213.
103. Darabi M, Lari MA, Motevalian SA, Motlagh A, Arsang-Jang S, Jaber MK. Trends in gastrointestinal cancer incidence in Iran, 2001–2010: a joinpoint analysis. *Epidemiol Health.* 2016;38:e2016056. doi:10.4178/epih.e2016056
104. Talaiezhadeh A, Tabesh H, Sattari A, Ebrahimi S. Cancer incidence in southwest of Iran: first report from khuzestan population-based cancer registry, 2002–2009. *Asian Pac J Cancer Prev.* 2013;14(12):7517–7522. doi:10.7314/APJCP.2013.14.12.7517
105. Norouzinia M, Asadzadeh H, Shalmani HM, Al Dulaimi D, Zali M. Clinical and histological indicators of proximal and distal gastric cancer in eight provinces of Iran. *Asian Pac J Cancer Prev.* 2012;13(11):5677–5679. doi:10.7314/APJCP.2012.13.11.5677
106. Askarian M, Goli A, Oroei M, Faramarzi H. The geographical clusters of gastrointestinal tract cancer in fars province, southern Iran. *Int J Prev Med.* 2014;5(7):857–864.
107. Norouzirad R, Khazaei Z, Mousavi M, et al. Epidemiology of common cancers in Dezful county, southwest of Iran. *Immunopathol Persa.* 2018;4(1):7.
108. Najafi F, Mozaffari H, Karami M, Izadi B, Tavvafzadeh R, Pasdar Y. Trends in incidence of gastrointestinal tract cancers in Western Iran, 1993–2007. *Iran Red Crescent Med.* 2011;13(11):805–810.
109. Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z. Cancer incidence and mortality in Iran. *Ann Oncol.* 2008;20(3):556–563.
110. Enayatradd M, Salehiniya H. Trends in gastric cancer incidence in Iran. *J Mazandaran Univ Med Sci.* 2014;24(114):8–16.
111. Haidari M, Nikbakht MR, Pasdar Y, Najafi F. Trend analysis of gastric cancer incidence in Iran and its six geographical areas during 2000–2005. *Asian Pac J Cancer Prev.* 2012;13(7):3335–3341. doi:10.7314/APJCP.2012.13.7.3335
112. Marzoni A-SH, Moghimbeigi A, Faradmal J. Gastric and esophageal cancers incidence mapping in golestan province, Iran: using Bayesian–Gibbs sampling. *Osong Public Health Res Perspect.* 2015;6(2):100–105. doi:10.1016/j.phrp.2015.01.004
113. Ahmadi Panahmehrabadi V, Hassanzadeh A, Mahaki B. Bivariate spatio-temporal shared component modeling: mapping of relative death risk due to colorectal and stomach cancers in Iran provinces. *Int J Prev Med.* 2019;10:39. doi:10.4103/ijpvm.IJPVM_31_17
114. Aghamohammadi S, Kazemi E, Khosravi A, Kazemeini H. The trend of ten leading causes of death in the Islamic Republic of Iran, 2006–2011. *IRJE.* 2017;12(4):1–11.
115. Amoori N, Mahdavi S, Enayatradd M. Epidemiology and trend of stomach cancer mortality in Iran. *Int J Epidemiol Res.* 2016;3(3):268–275.
116. Khorasani S, Rezaei S, Rashidian H, Daroudi R. Years of potential life lost and productivity costs due to premature cancer-related mortality in Iran. *Asian Pac J Cancer Prev.* 2015;16(5):1845–1850. doi:10.7314/APJCP.2015.16.5.1845
117. Nalini M, Oranuba E, Poustchi H, et al. Causes of premature death and their associated risk factors in the Golestan Cohort Study, Iran. *BMJ Open.* 2018;8(7):e021479. doi:10.1136/bmjopen-2018-021479
118. Mohammadi G, Akbari ME, Mehrabi Y, Motlagh AG, Heidari M, Ghanbari S. Analysis of cancer incidence and mortality in Iran using joinpoint regression analysis. *Iran Red Crescent Med J.* 2017;19:3.
119. Malekzadeh MM, Khademi H, Pourshams A, et al. Opium use and risk of mortality from digestive diseases: a prospective cohort study. *Am J Gastroenterol.* 2013;108(11):1757. doi:10.1038/ajg.2013.336
120. Ostadrahimi A, Payahoo L, Somi MH, Khajebishak Y. The association between urinary cadmium levels and dietary habits with risk of gastrointestinal cancer in Tabriz, Northwest of Iran. *Biol Trace Elem Res.* 2017;175(1):72–78. doi:10.1007/s12011-016-0764-6
121. Islami F, Kamangar F, Aghcheli K, et al. Epidemiologic features of upper gastrointestinal tract cancers in Northeastern Iran. *British Journal of Cancer.* 2004;90(7):1402. doi:10.1038/sj.bjc.6601737
122. Barekat AA, Saidi F, Dutz W. Cancer survey in south Iran with special reference to gastrointestinal neoplasms. *Int J Cancer.* 1971;7(2):353–363. doi:10.1002/ijc.2910070221
123. Bashash M, Yavari P, Hislop TG, et al. Comparison of two diverse populations, British Columbia, Canada, and Ardabil, Iran, indicates several variables associated with gastric and esophageal cancer survival. *J Gastrointest Cancer.* 2011;42(1):40–45. doi:10.1007/s12029-010-9228-y
124. Pourhoseingholi A, Pourhoseingholi MA, Vahedi M, et al. Relation between demographic factors and type of gastrointestinal cancer using probit and logit regression. *Asian Pac J Cancer Prev.* 2008;9(4):753–755.
125. Tabrizchee H, Masoomian M, Ahani F, Zare M. The pattern of malignant Tumors in Kerman province. *MJIRI.* 1998;12(1):19–23.
126. Tavoli A, Mohagheghi MA, Montazeri A, Roshan R, Tavoli Z, Omidvari S. Anxiety and depression in patients with gastrointestinal cancer: does knowledge of cancer diagnosis matter? *BMC Gastroenterol.* 2007;7(1):28. doi:10.1186/1471-230X-7-28

127. Hajmanoochehri F, Mohammadi N, Nasirian N, Hosseinkhani M. Patho-epidemiological features of esophageal and gastric cancers in an endemic region: a 20-year retrospective study. *Asian Pac J Cancer Prev*. 2013;14(6):3491–3497. doi:10.7314/APJCP.2013.14.6.3491
128. Khademloo M, Moosazadeh M, Ahmadi M, Alizadeh-Navaei R. Geographical distribution of gastric cancer in north of Iran—a cross-sectional study. *World Cancer Res J*. 2018;5(1):e1050.
129. Tayebi M, Shabestani Monfared A, Moslemi D. A 10 year survey of cancer in patients who referred to Shahid Rajai Radiotherapy Center in North of Iran (2000-2009). *J BU MS*. 2012;14(6):97–101.
130. Nikfarjam Z, Massoudi T, Salehi M, Salehi M, Khoshroo F. Demographic survey of four thousand patients with 10 common cancers in North Eastern Iran over the past three decades. *Asian Pac J Cancer Prev*. 2014;15(23):10193–10198. doi:10.7314/APJCP.2014.15.23.10193
131. Hashemi SM, Mashhadi M, Moghaddam AA, et al. The relationship between serum selenium and zinc with gastroesophageal cancers in the Southeast of Iran. *Indian J Med Paediatr Oncol*. 2017;38(2):169.
132. Yazdizadeh B, Jarrahi A, Mortazavi H, Mohagheghi MA, Tahmasebi S, Nahvijo A. Time trends in the occurrence of major GI cancers in Iran. *Asian Pac J Cancer Prev*. 2005;6(2):130–134.
133. Mehrabian A, Esna-Ashari F, Zham H, et al. Gastric cancer prevalence, according to survival data in Iran (National Study-2007). *Iran J Public Health*. 2010;39(3):27–31.
134. Kadivar M, Rahimabad PK. Missing elements in surgical pathology reports: breast, Colon and Stomach Cancers. *Asian Pac J Cancer Prev*. 2016;17(3):1469–1472. doi:10.7314/APJCP.2016.17.3.1469
135. Karami K, Cheraghi M, Amori N, Pedram M, Sobhani A. Common cancers in Khuzestan province, south west of Iran, during 2005-2011. *Asian Pac J Cancer Prev*. 2014;15(21):9475–9478. doi:10.7314/APJCP.2014.15.21.9475
136. Boreiri M, Samadi F, Etemadi A, et al. Gastric cancer mortality in a high incidence area: long-term follow-up of *Helicobacter pylori*-related precancerous lesions in the general population. *Arch Iran Med*. 2013;16(6):343–347.
137. Moghimi-Dehkordi B, Safaee A, Vahedi M, et al. Familial prevalence of cancer in Iran: a general population estimate. *Asian Pac J Cancer Prev*. 2011;12(1):289–295.
138. Zendehehd N, MASARAT S, SHEYKH AA, et al. Topography of gastritis and its severity in 864 first degree relatives of gastric cancer patients. *Arch Iran Med*. 2010;13(6):469–475.
139. Ahmadi K, Soleimani A, Irani S, et al. DNMT3B- 579 G> T promoter polymorphism and the risk of gastric cancer in the West of Iran. *J Gastrointest Cancer*. 2018;49(2):167–171. doi:10.1007/s12029-017-9928-7
140. Azarbarzin S, Safaralizadeh R, Kazemzadeh M, Fateh A. The value of MiR-383, an intronic MiRNA, as a diagnostic and prognostic biomarker in intestinal-type gastric cancer. *Biochem Genet*. 2017;55(3):244–252. doi:10.1007/s10528-017-9793-x
141. Azarkhazin F, Tehrani A. Detecting promoter methylation pattern of apoptotic genes Apaf1 and Caspase8 in gastric carcinoma patients undergoing chemotherapy. *J Gastrointest Oncol*. 2018;9(2):295–302.
142. Azarhoush R, KESHTKAR AA, AMIRIAN T, KAZEMINEZHAD. Relationship Between P53 Expression and Gastric Cancers in Cardia and Antrum. *Arch Iran Med*. 2008;11(5):502–506.
143. Asadi MH, Mowla SJ, Fathi F, Aleyasin A, Asadzadeh J, Atlasi Y. OCT4B1, a novel spliced variant of OCT4, is highly expressed in gastric cancer and acts as an antiapoptotic factor. *Int J Cancer*. 2011;128(11):2645–2652. doi:10.1002/ijc.25643
144. Ismaili A, Yari K, Moradi M-T, et al. IL-1B (C+ 3954T) gene polymorphism and susceptibility to gastric cancer in the Iranian population. *Asian Pac J Cancer Prev*. 2015;16:841–844. doi:10.7314/APJCP.2015.16.2.841
145. Aghdam SM, Sardari Z, Safaralizadeh R, et al. Investigation of association between oipA and iceA1/iceA2 genotypes of *Helicobacter pylori* and gastric cancer in Iran. *Asian Pac J Cancer Prev*. 2014;15(19):8295–8299. doi:10.7314/APJCP.2014.15.19.8295
146. Akrami H, Mahmoodi F, Havasi S, Sharifi A. PIGF knockdown inhibited tumor survival and migration in gastric cancer cell via PI3K/Akt and p38MAPK pathways. *Cell Biochem Funct*. 2016;34(3):173–180. doi:10.1002/cbf.3176
147. Amouei S, Attaranzadeh A, Montazer M. Intratumoral CD68-, CD117-, CD56-, and CD1a-positive immune cells and the survival of Iranian patients with non-metastatic intestinal-type gastric carcinoma. *Pathol Res Pract*. 2015;211(4):326–331. doi:10.1016/j.prp.2014.12.013
148. Amini M, Foroughi K, Talebi F, et al. GHSR DNA hypermethylation is a new epigenetic biomarker for gastric adenocarcinoma and beyond. *J Cell Physiol*. 2019;1–10.
149. Iranpour M, Nourian M, Saffari S, et al. PIK3CA mutation analysis in iranian patients with gastric cancer. *Iran Biomed J*. 2019;23(1):87–91. doi:10.29252/ibj.23.1.87
150. Ayremlou N, Mozdarani H, Mowla SJ, Delavari A. Increased levels of serum and tissue miR-107 in human gastric cancer: correlation with tumor hypoxia. *Cancer Biomark*. 2015;15(6):851–860. doi:10.3233/CBM-150529
151. Basi A, Raoofi A, Vaseghi H, Zare-Mehrjardi A. Study of HER2 expression and its relation to tumor characteristics among gastric adenocarcinoma patients of Firoozgar hospital, Tehran, Iran; in 2010 and 2011. *Int J Hematol Oncol Stem Cell Res*. 2012;6(4):25–29.
152. Bagheri V, Abbaszadegan MR, Memar B, et al. Induction of T cell-mediated immune response by dendritic cells pulsed with mRNA of sphere-forming cells isolated from patients with gastric cancer. *Life Sci*. 2019;219:136–143. doi:10.1016/j.lfs.2019.01.016
153. Bagheri N, Azadegan-Dehkordi F, Sanehi H, et al. Associations of a TLR4 single-nucleotide polymorphism with *H. pylori* associated gastric diseases in iranian patients. *Clin Res Hepatol Gastroenterol*. 2014;38(3):366–371. doi:10.1016/j.clinre.2013.12.004
154. Bagheri N, Sadeghiani M, Rahimian G, et al. Correlation between expression of MMP-9 and MMP-3 in *Helicobacter pylori* infected patients with different gastroduodenal diseases. *Arab J Gastroenterol*. 2018;19(4):148–154. doi:10.1016/j.ajg.2018.11.001
155. Basati G, Mohammadpour H, Emami-Razavi A. Low expression levels of peroxisome proliferator-activated receptor gamma (PPARγ) in gastric cancer and its relationship with tumor progression. *J Isfahan Med Sch*. 2017;35(440):911–918.
156. Basiri Z, Safaralizadeh R, Bonyadi MJ, Somi MH, Mahdavi M, Latifi-Navid S. *Helicobacter pylori* vacA d1 genotype predicts risk of gastric adenocarcinoma and peptic ulcers in northwestern Iran. *Asian Pac J Cancer Prev*. 2014;15(4):1575–1579. doi:10.7314/APJCP.2014.15.4.1575
157. Bahadori A, Somi MH, Doran F, et al. Determination of correlation between principal genotypes of *Helicobacter pylori* according to cagPAI components and vacA genotypes and clinical outcome in patients suffering from active chronic gastritis and gastric adenocarcinoma from Iran and Turkey. *Biomed Res*. 2017;28(4):1743–1748.
158. Bahadori A, SOMI MH, Doran F, et al. Comparative analysis of selected cagPAI genes and different vacA genotypes in Iranian and Turkish *H. pylori*-positive patients suffering from gastric adenocarcinoma and active chronic gastritis. *Turk J Med Sci*. 2017;47(3):916–922.
159. Bahari F, Emadi-Baygi M, Nikpour P. miR-17-92 host gene, underexpressed in gastric cancer and its expression was negatively correlated with the metastasis. *Indian J Cancer*. 2015;52(1):22. doi:10.4103/0019-509X.175605

160. Beheshtizadeh M, Moslemi E. Analysis of G3BP1 and VEZT expression in gastric cancer and their possible correlation with tumor clinicopathological factors. *Journal of Gastric Cancer*. 2017;17(1):43–51. doi:10.5230/jgc.2017.17.e5
161. Bohlooli S, Jafari N, Jahed S. Cytotoxic effect of freeze-dried extract of Ecballium elaterium fruit on gastric adenocarcinoma (AGS) and esophageal squamous cell carcinoma (KYSE30) cell lines. *J Gastrointest Cancer*. 2012;43(4):579–583. doi:10.1007/s12029-012-9383-4
162. Baygi ME, Nikpour P. Deregulation of MTDH gene expression in gastric cancer. *Asian Pac J Cancer Prev*. 2012;13(6):2833–2836. doi:10.7314/APJCP.2012.13.6.2833
163. Savabkar S, Azimzadeh P, Chaleshi V, Mojarad EN, Aghdaei HA. Programmed death-1 gene polymorphism (PD-1.5 C/T) is associated with gastric cancer. *Gastroenterol Hepatol Bed Bench*. 2013;6(4):178–182.
164. Janbabai G, Oladi Z, Farazmandfar T, Taghvaei T, Naghshvar F. The prognostic impact of EGFR, ErbB2 and MET gene amplification in human gastric carcinomas as measured by quantitative Real-Time PCR. *J Cancer Res Clin Oncol*. 2015;141(11):1945–1952. doi:10.1007/s00432-015-1965-7
165. Jafargholizadeh N, Zargar SJ, Aftabi Y. The cucurbitacins D, E, and I from Ecballium elaterium (L.) upregulate the LC3 gene and induce cell-cycle arrest in human gastric cancer cell line AGS. *Iran J Basic Med Sci*. 2018;21(3):253.
166. Jafari F, Shokrzadeh L, Dabiri H, et al. vacA genotypes of Helicobacter pylori in relation to cagA status and clinical outcomes in Iranian populations. *Jpn J Infect Dis*. 2008;61(4):290–293.
167. Javanbakht M, Akhavanmoghadam J, Talaei AJ, et al. Differential expression of two genes Oct-4 and MUC 5 AC associates with poor outcome in patients with gastric cancer. *Clin Exp Pharmacol Physiol*. 2017;44(11):1099–1105. doi:10.1111/1440-1681.12840
168. Jeivad F, Abediankenari S, Shokrzadeh M, et al. Tyrosine kinase domain gene polymorphism of epidermal growth factor receptor in gastric cancer in northern Iran. *Tehran Univ Med J*. 2012;69(10):619–623.
169. Cherati MR, Shokri-Shirvani J, Karkhah A, Rajabnia R, Nouri HR. Helicobacter pylori cagL amino acid polymorphism D58E59 pave the way toward peptic ulcer disease while N58E59 is associated with gastric cancer in north of Iran. *Microb Pathog*. 2017;107:413–418. doi:10.1016/j.micpath.2017.04.025
170. Hafezi N, Ajami A, Farazmandfar T, Hosseini V, ALIZADEH NR, Tehrani M. Increased expression of two alternative spliced variants of CD1d molecule in human gastric cancer. *Iran J Immunol*. 2015;12(2):129–140.
171. Habibzadeh M, Tourani M, Shokri-Shirvani J, Mostafazadeh A, Khafri S, Nouri HR. TLR2 Arg677Trp but not TLR2-196 to-174 ins/del and Arg753Gln polymorphism alter the risk of peptic ulcer in north of Iran. *J Chin Med Assoc*. 2018;81(1):25–30. doi:10.1016/j.jcma.2017.05.009
172. Habibi A, Ranjbari N, Rahim F, Jazayeri N. Correlation between CD34 Marker and clinico-pathologic characteristics of gastric cancer. *Cancer Res*. 2015;11(3):136–142.
173. Hosseinzadeh A, Ardebili SMM. Efficacy of omega fatty acid supplementation on mRNA expression level of tumor necrosis factor alpha in patients with gastric adenocarcinoma. *J Gastrointest Cancer*. 2016;47(3):287–293. doi:10.1007/s12029-016-9826-4
174. Hussein N. The association of dupA and Helicobacter pylori-related gastroduodenal diseases. *Eur J Clin Microbiol Infect Dis*. 2010;29(7):817–821. doi:10.1007/s10096-010-0933-z
175. Haghshenas MR, Hosseini SV, Mahmoudi M, Saberi-Firozi M, Farjadian S, Ghaderi A. IL-18 serum level and IL-18 promoter gene polymorphism in Iranian patients with gastrointestinal cancers. *J Gastroenterol Hepatol*. 2009;24(6):1119–1122.
176. Heidari K, Nezhad VK, Noroozi A, Mehravar F. The Prevalence of Helicobacter pylori Virulence Related Genes (hpa and babA2) in Iranian patients with gastrointestinal disorders. *Jundishapur J Microbiol*. 2017;10:12. doi:10.5812/jjm.60947
177. Heydari-Mehrabadi A, Tamandani DMK, Baranzehi T, Hemati S. Analysis of polymorphism and expression profile of ASIC1 and IL-6 genes in patients with gastric cancer. *Asian Pac J Cancer Preve*. 2018;19(12):3451–3455. doi:10.31557/APJCP.2018.19.12.3451
178. Khatami F, Noorinayer B, Ghiasi S, Mohebi R, Hashemi M, Zali MR. Lack of effects of single nucleotide polymorphisms of the DNA methyltransferase 1 gene on gastric cancer in Iranian patients: a case control study. *Asian Pac J Cancer Prev*. 2009;10(6):1177–1182.
179. Khaleghian M, Shakoobi A, Razavi AE, Azimi C. Relationship of amplification and expression of the C-MYC gene with survival among gastric cancer patients. *Asian Pac J Cancer Prev*. 2015;16(16):7061–7069. doi:10.7314/APJCP.2015.16.16.7061
180. Khalili M, Vasei M, Khalili D, Alimoghaddam K, Sadeghizadeh M, Mowla SJ. Downregulation of the genes involved in reprogramming (SOX2, c-MYC, miR-302, miR-145, and P21) in gastric adenocarcinoma. *J Gastrointest Cancer*. 2015;46(3):251–258. doi:10.1007/s12029-015-9695-2
181. Khalili M, Sadeghizadeh M, Ghorbanian K, Malekzadeh R, Vasei M, Mowla SJ. Down-regulation of miR-302b, an ESC-specific microRNA, in gastric adenocarcinoma. *Cell J*. 2012;13(4):251–258.
182. Daneshpour M, Karimi B, Omidfar K. Simultaneous detection of gastric cancer-involved miR-106a and let-7a through a dual-signal-marked electrochemical nanobiosensor. *Biosens Bioelectron*. 2018;109:197–205. doi:10.1016/j.bios.2018.03.022
183. Salehi Z, Akrami H. Target genes prediction and functional analysis of microRNAs differentially expressed in gastric cancer stem cells MKN-45. *J Cancer Res Ther*. 2017;13(3):477–483.
184. Sabahi Z, Salek R, Heravi R, Mosaffa F, Avanaki Z, Behravan J. Association of gastric cancer incidence with MDR1 gene polymorphism in an ethnic Iranian population. *Indian J Cancer*. 2010;47(3):317–321. doi:10.4103/0019-509X.64723
185. Sedarat Z, Khashei R, Shirzad H, et al. Frequency of helicobacter pylori hopQI, hopQII and sabA genes among Iranian patients with gastroduodenal diseases. *Jundishapur J Microbiol*. 2018;11(8):e56017. doi:10.5812/jjm.56017
186. Souod N, Kargar M, Doosti A, Ranjbar R, Sarshar M. Genetic analysis of cagA and vacA genes in Helicobacter pylori isolates and their relationship with gastroduodenal diseases in the west of Iran. *Iran Red Crescent Med J*. 2013;15(5):371–375. doi:10.5812/ircmj.3732
187. Safaralizadeh R, Ajami N, Nemati M, Hosseinpourfeizi M, Isfanzani AA, Moaddab S-Y. Disregulation of miR-216a and miR-217 in gastric cancer and their clinical significance. *J Gastrointest Cancer*. 2019;50(1):78–83. doi:10.1007/s12029-017-0019-6
188. Abadi ATB, Rafiei A, Ajami A, et al. Helicobacter pylori homB, but not cagA, is associated with gastric cancer in Iran. *J Clin Microbiol*. 2011;49(9):3191–3197.
189. Abadi ATB, Taghvaei T, Wolfram L, Kusters JG. Infection with Helicobacter pylori strains lacking dupA is associated with an increased risk of gastric ulcer and gastric cancer development. *J Med Microbiol*. 2012;61(1):23–30. doi:10.1099/jmm.0.027052-0
190. Abadi ATB, Taghvaei T, Mobarez AM, Vaira G, Vaira D. High correlation of babA 2-positive strains of Helicobacter pylori with the presence of gastric cancer. *Intern Emerg Med*. 2013;8(6):497–501. doi:10.1007/s11739-011-0631-6
191. Abediankenari S, Jeivad F. Epidermal growth factor receptor gene polymorphisms and gastric cancer in Iran. *Asian Pac J Cancer Prev*. 2013;14(5):3187–3190. doi:10.7314/APJCP.2013.14.5.3187

192. Abdi E, Latifi-Navid S, Yazdanbod A, Zahri S. Helicobacter pylori babA2 positivity predicts risk of gastric cancer in Ardabil, a very high-risk area in Iran. *Asian Pac J Cancer Prev*. 2016;17(2):733–738. doi:10.7314/APJCP.2016.17.2.733
193. Ezzeddini R, Taghikhani M, Somi MH, Samadi N, Rasaei MJ. Clinical importance of FASN in relation to HIF-1 α and SREBP-1c in gastric adenocarcinoma. *Life Sci*. 2019;224:169–176. doi:10.1016/j.lfs.2019.03.056
194. Effatpanah H, Yadegarazari R, Karami M, Majlesi A, Shabab N, Saidijam M. Expression analysis of mir-21 and mir-221 in cancerous tissues from Iranian patients with gastric cancer. *Iran Biomed J*. 2015;19(4):188–193.
195. Oghalaie A, Saberi S, Esmaili M, et al. Helicobacter pylori peptidyl prolyl isomerase expression is associated with the severity of gastritis. *J Gastrointest Cancer*. 2016;47(4):375–380. doi:10.1007/s12029-016-9849-x
196. Dabiri H, Jafari F, Baghaei K, et al. Prevalence of Helicobacter pylori vacA, cagA, cagE, oipA, iceA, babA2 and babB genotypes in Iranian dyspeptic patients. *Microb Pathog*. 2017;105:226–230. doi:10.1016/j.micpath.2017.02.018
197. Alghalandis LD, Shahsavani R, Ghavamzadeh A, et al. Development of a quantitative Real-Time PCR for micrometastasis detection using CEA in peripheral blood and bone marrow specimens of gastric cancer patients. *Tehran Univ Med J*. 2009;67(8):542–548.
198. Dardaei L, Shahsavani R, Ghavamzadeh A, et al. The detection of disseminated tumor cells in bone marrow and peripheral blood of gastric cancer patients by multimarker (CEA, CK20, TFF1 and MUC2) quantitative real-time PCR. *Clinical Chemists*. 2011;44(4):325–330.
199. Dastjerdi MN, Kavosi F, Valiani A, et al. Inhibitory effect of genistein on PLC/PRF5 hepatocellular carcinoma cell line. *Int J PrevMed*. 2015;6:54. doi:10.4103/2008-7802.158914
200. Douraghi M, Talebkhan Y, Zeraati H, et al. Multiple gene status in Helicobacter pylori strains and risk of gastric cancer development. *Digestion*. 2009;80(3):200–207. doi:10.1159/000229774
201. Razmkhah M, Ghaderi A. SDF-1 α G801A polymorphism in Southern Iranian patients with colorectal and gastric cancers. *Indian J Gastroenterol*. 2013;32(1):28–31. doi:10.1007/s12664-012-0283-0
202. Rostami M, Kalaei Z, Pourhoseingholi MA, Kadivar M. Study on association between H-ras gene polymorphism and gastric adenocarcinoma risk. *Gastroenterol Hepatol Bed Bench*. 2013;6(3):146–151.
203. Zare A, Ahadi A, Larki P, et al. The clinical significance of miR-335, miR-124, miR-218 and miR-484 downregulation in gastric cancer. *Mol Biol Rep*. 2018;45(6):1587–1595. doi:10.1007/s11033-018-4278-5
204. Zare A, Alipoor B, Omrani MD, Zali MR, Alamdari NM, Ghaedi H. Decreased miR-155-5p, miR-15a, and miR-186 expression in gastric cancer is associated with advanced tumor grade and metastasis. *Iran Biomed J*. 2019;23(5):338. doi:10.29252/ibj.23.5.5
205. Zandi S, Hedayati MA, Mohammadi E, Sheikhesmaeili F. Helicobacter pylori infection increases sirt2 gene expression in gastric epithelial cells of gastritis patients. *Microb Pathog*. 2018;116:120–123. doi:10.1016/j.micpath.2017.12.078
206. Sadjadi A, Yazdanbod A, Lee YY, et al. Serum ghrelin; a new surrogate marker of gastric mucosal alterations in upper gastrointestinal carcinogenesis. *PLoS One*. 2013;8(9):e74440. doi:10.1371/journal.pone.0074440
207. Saadat I, Saadat M. Glutathione S-transferase M1 and T1 null genotypes and the risk of gastric and colorectal cancers. *Cancer Lett*. 2001;169(1):21–26. doi:10.1016/S0304-3835(01)00550-X
208. Soleimani A, Ghanadi K, Noormohammadi Z, Irani S. The correlation between miR-146a C/G polymorphism and UHRF1 gene expression level in gastric tumor. *J Dig Dis*. 2016;17(3):169–174. doi:10.1111/1751-2980.12329
209. Sohrabi S, Effatpanah H, Shabab N, Saidijam M. Expression analysis of PTEN and CDKN1C/p57kip2 in cancerous tissues from Iranian patients with gastric cancer. *Eur J Oncol*. 2017;22(2):88–94.
210. Shakhoseini Z, Jeivad F, Ahangar N, Abediankenari S. Different genotype of rs3130932 single nucleotide polymorphism between gastric cancer patients and normal subjects. *J Gastrointest Cancer*. 2017;48(1):38–41. doi:10.1007/s12029-016-9869-6
211. Saberi S, Zendehele K, Jahangiri S, et al. Impact of methylenetetrahydrofolate reductase C677T polymorphism on the risk of gastric cancer and its interaction with Helicobacter pylori infection. *Iran Biomed J*. 2012;16(4):179–184.
212. Imani-Saber Z, Yousefi-Razin E, Javaheri M, Mirfakhraie R, Motalleb G, Ghafouri-Fard S. Promyelocytic leukemia (PML) gene mutations may not contribute to gastric adenocarcinoma development. *Asian Pac J Cancer Prev*. 2015;16(8):3523–3525. doi:10.7314/APJCP.2015.16.8.3523
213. Masoudi M, Saadat I, Omidvari S, Saadat M. Genetic polymorphisms of GSTO2, GSTM1, and GSTT1 and risk of gastric cancer. *Mol Biol Rep*. 2009;36(4):781–784. doi:10.1007/s11033-008-9245-0
214. Moghanibashi M, Mohamadynejad P, Rasekhi M, Ghaderi A, Mohammadianpanah M. Polymorphism of estrogen response element in TFF1 gene promoter is associated with an increased susceptibility to gastric cancer. *Gene*. 2012;492(1):100–103. doi:10.1016/j.gene.2011.10.048
215. Moghbeli M, Moaven O, Memar B, et al. Role of hMLH1 and E-cadherin promoter methylation in gastric cancer progression. *J Gastrointest Cancer*. 2014;45(1):40–47. doi:10.1007/s12029-013-9548-9
216. Moghbeli M, Makhdoomi Y, Delgosha MS, et al. Erbb1 and Erbb3 co-over expression as a prognostic factor in gastric cancer. *Biol Res*. 2019;52(1):2. doi:10.1186/s40659-018-0208-1
217. Mokmeli S, Tehrani GA, Zamiri RE, Bahrami T. Investigating the frequency of the ERCC1 Gene C8092A polymorphism in Iranian patients with advanced gastric cancer. *Asian Pac J Cancer Prev*. 2016;17(3):1369–1372. doi:10.7314/APJCP.2016.17.3.1369
218. Malek-Hosseini Z, Taherinejad M, Malekzadeh M, Ghaderi A, Doroudchi M. IL-17A levels in the sera of patients with gastric cancer show limited elevation. *Asian Pac J Cancer Prev*. 2015;16:7149–7153. doi:10.7314/APJCP.2015.16.16.7149
219. Mansoori M, Ghalipour M, Alizadeh S, et al. Genetic Variation in the ABCB1 gene may lead to mRNA level change: application to gastric cancer cases. *Asian Pac J Cancer Prev*. 2015;16(18):8467–8471. doi:10.7314/APJCP.2015.16.18.8467
220. Mirmajidi SH, Ataee R, Barzegar A, Nikbakht N, Shaterpour M. Low Expression of the bcl2 Gene in Gastric Adenocarcinomas in Mazandaran Province of Iran. *Asian Pac J Cancer Prev*. 2015;16(14):6067–6071. doi:10.7314/APJCP.2015.16.14.6067
221. Sadeghi RN, Azimzadeh P, Vahedi M, et al. Profile and frequency of p53 gene alterations in gastritis lesions from Iran. *Digestion*. 2011;83(1–2):65–75. doi:10.1159/000320690
222. Najafzadeh N, Mazani M, Abbasi A, Farassati F, Amani M. Low-dose all-trans retinoic acid enhances cytotoxicity of cisplatin and 5-fluorouracil on CD44+ cancer stem cells. *Biomed Pharmacother*. 2015;74(243–51.4):243–251. doi:10.1016/j.biopha.2015.08.019
223. Norollahi SE, Alipoor M, Rashidy-Pour A, Samadani AA, Larijani LV. Regulatory fluctuation of WNT16 gene expression is associated with human gastric adenocarcinoma. *J Gastrointest Cancer*. 2019;50(1):42–47. doi:10.1007/s12029-017-0022-y
224. Noormohammad M, Sadeghi S, Tabatabaeian H, et al. Upregulation of miR-222 in both Helicobacter pylori-infected and noninfected gastric cancer patients. *J Genet*. 2016;95(4):991–995. doi:10.1007/s12041-016-0728-9

225. Nikpour P, Emadi-Baygi M, Mohamad-Hashem F, Maracy MR, Haghooy-Javanmard S. MSI1 overexpression in diffuse type of gastric cancer. *Pathol Res Pract*. 2013;209(1):10–13. doi:10.1016/j.prp.2012.09.008
226. Nikpour P, Emadi-Baygi M, Emadi-Andani E, Rahmati S. EYA1 expression in gastric carcinoma and its association with clinicopathological characteristics: a pilot study. *Med Oncol*. 2014;31(5):955. doi:10.1007/s12032-014-0955-y
227. Nikpour P, Emadi-Baygi M, Mohammad-Hashem F, Maracy MR, Haghooy-Javanmard S. Differential expression of ZFX gene in gastric cancer. *J Biosci*. 2012;37(1):85–90. doi:10.1007/s12038-011-9174-2
228. Hajjari M, Behmanesh M, Sadeghizadeh M, Zeinoddini M. Up-regulation of HOTAIR long non-coding RNA in human gastric adenocarcinoma tissues. *Med Oncol*. 2013;30(3):670. doi:10.1007/s12032-013-0670-0
229. Hedayatizadeh-Omran A, Alizadeh-Navaei R, Janabaei G, et al. Association of P53 gene polymorphism with gastric cancer in Northern Iran as a high-risk region. *Biomed Rep*. 2018;8(5):433–438.
230. Hadinia A, Hossieni SV, Erfani N, Saberi-Firozi M, Fattahi MJ, Ghaderi A. CTLA-4 gene promoter and exon 1 polymorphisms in Iranian patients with gastric and colorectal cancers. *JGH Open*. 2007;22(12):2283–2287.
231. Andalib A, Doulabi H, Maracy MR, Rezaei A, Hasheminia SJ. CCR3, CCR4, CCR5, and CXCR3 expression in peripheral blood CD4+ lymphocytes in gastric cancer patients. *Adv Biomed Res*. 2013;2:31. doi:10.4103/2277-9175.108770
232. Farahani RK, Azimzadeh P, Rostami E, et al. Evaluation of insulin like growth factor-1 genetic polymorphism with gastric cancer susceptibility and clinicopathological features. *Asian Pac J Cancer Prev*. 2015;16(10):4215–4218. doi:10.7314/APJCP.2015.16.10.4215
233. Farjadian S, Tabebordbar M, Mokhtari M, Safaei A, Malekzadeh M, Ghaderi A. Expression in tumor tissues and soluble HLA-G plasma levels in patients with gastrointestinal cancer. *Asian Pac J Cancer Prev*. 2018;19(10):2731.
234. Hemati M, Mansourabadi AH, Bafghi MK, Moradi A. Association between paraoxonase-1 gene Q192R and L55M polymorphisms and risk of gastric cancer: A case-control study from Iran. *Nucleosides Nucleotides Nucleic Acids*. 2019;38(7):521–532. doi:10.1080/15257770.2019.1573371
235. Honarmand-Jahromy S, Siavoshi F, Malekzadeh R, Sattari TN, Latifi-Navid S. Multiple repeats of Helicobacter pylori CagA EPIYA-C phosphorylation sites predict risk of gastric ulcer in Iran. *Microb Pathog*. 2015;89:87–92. doi:10.1016/j.micpath.2015.09.005
236. Latifi-Navid S, Mohammadi S, Maleki P, et al. Helicobacter pylori vacA d1/i1 genotypes and geographic differentiation between high and low incidence areas of gastric cancer in Iran. *Arch IranMed*. 2013;16(6):330–337.
237. Mottaghi B, Safaralizadeh R, Bonyadi M, Latifi-Navid S, Somi MH. Helicobacter pylori vacA i region polymorphism but not babA2 status associated to gastric cancer risk in northwestern Iran. *Clin Exp Med*. 2016;16(1):57–63. doi:10.1007/s10238-014-0327-0
238. Motovali-Bashi M, Hamidy M. Association between GT-repeat polymorphism at heme oxygenase-1 gene promoter and gastric cancer and metastasis. *Tumour Biol*. 2015;36(6):4757–4762. doi:10.1007/s13277-015-3125-8
239. Mojtahedi Z, Haghsheenas M, Hosseini S, Fattahi M, Ghaderi A. p 53 codon 72 polymorphism in stomach and colorectal adenocarcinomas in Iranian patients. *Indian J Cancer*. 2010;47(1):31–34. doi:10.4103/0019-509X.58856
240. Mohsenzadeh M, Sadeghi RN, Vahedi M, et al. Promoter hypermethylation of RAR-β tumor suppressor gene in gastric carcinoma: association with histological type and clinical outcomes. *Cancer Biomark*. 2017;20(1):7–15. doi:10.3233/CBM-160331
241. Mohammadi S, Mohamadynejad P, Moghanibashi M. Increased risk of gastric cancer with VNTR polymorphism of SIRT3 Gene. *J Mazandaran Univ Med Sci*. 2017;27(152):23–30.
242. Mohammadian F, Pilehvar-Soltanahmadi Y, Mofarrah M, Dastani-Habashi M, Zarghami N. Down regulation of miR-18a, miR-21 and miR-221 genes in gastric cancer cell line by chrysin-loaded PLGA-PEG nanoparticles. *Artif Cells Nanomed Biotechnol*. 2016;44(8):1972–1978. doi:10.3109/21691401.2015.1129615
243. Mohamadkhani A, Moghaddam SD, Salmanroghani H, et al. Are the serum biomarkers pepsinogen I and II good predictors for the detection of subjects with atrophic gastritis in areas that have different gastric cancer incidence? *Arch Iranian Med*. 2013;16(4):208–212.
244. Mohammadi M, Zarghami N, Hedayati M, Ghaemmaghami S, Yamchi R, Mohaddes M. Visfatin effects on telomerase gene expression in AGS gastric cancer cell line. *Indian J Cancer*. 2015;52(1):32–35. doi:10.4103/0019-509X.175567
245. Madani S-H, Rahmati A, Sadeghi E, et al. Survey of Her2-neu expression and its correlation with histology of gastric carcinoma and gastroesophageal junction adenocarcinoma. *Asian Pac J Cancer Prev*. 2015;16(17):7755–7758. doi:10.7314/APJCP.2015.16.17.7755
246. Moradi M-T, Salehi Z, Aminian K, Yazdanbod A. Effects of p53 codon 72 and MDM2 SNP309 polymorphisms on gastric cancer risk among the Iranian population. *Asian Pac J Cancer Prev*. 2014;15(17):7413–7417. doi:10.7314/APJCP.2014.15.17.7413
247. Moradi M-T, Yari K, Rahimi Z, Kazemi E, Shabbazi M. Manganese superoxide dismutase (MnSOD Val-9Ala) gene polymorphism and susceptibility to gastric cancer. *Asian Pac J Cancer Prev*. 2015;16(2):485–488. doi:10.7314/APJCP.2015.16.2.485
248. Moradi M-T, Yari K, Rahimi Z. The GPX1 Pro 198 Leu polymorphism in gastric cancer patients with and without Helicobacter pylori infection. *Genes Genomics*. 2017;39(11):1265–1269. doi:10.1007/s13258-017-0594-8
249. Ghaedi H, Mozaffari MAN, Salehi Z, et al. Co-expression profiling of plasma miRNAs and long noncoding RNAs in gastric cancer patients. *Gene*. 2019;687:135–142. doi:10.1016/j.gene.2018.11.034
250. Ghalandary M, Behmanesh M, Sadeghizadeh M. Evaluating of suppressor of zeste 12 and chromobox homolog 8 genes expression showed two possible origins for gastric cancer development. *Indian J Cancer*. 2015;52(1):27–31. doi:10.4103/0019-509X.175566
251. Kashfi SMH, Farahbakhsh FB, Mojarad EN, et al. Interleukin-16 polymorphisms as new promising biomarkers for risk of gastric cancer. *Tumour Biol*. 2016;37(2):2119–2126. doi:10.1007/s13277-015-4013-y
252. Kordi Tamandani DM, Hemati S, Davani SK, Arbabi F. Association between promoter methylation and expression of thyroid hormone receptor beta (THR β) gene in patients with gastric cancer in an Iranian population. *J Gastroenterol Hepatol*. 2015;30(3):485–489. doi:10.1111/jgh.12808
253. Kalantari E, Asadi Lari MH, Roudi R, Korourian A, Madjd Z. Lgr5High/DCLK1High phenotype is more common in early stage and intestinal subtypes of gastric carcinomas. *Biomark Cancer*. 2017;20(4):563–573. doi:10.3233/CBM-170383
254. Kamalidehghan B, Houshmand M, Panahi MSS, Abbaszadegan MR, Ismail P, Shiroudi MB. Tumoral Cell mtDNA ~ 8.9 kb deletion is more common than other deletions in gastric cancer. *Arch Med Res*. 2006;37(7):848–853. doi:10.1016/j.arcmed.2006.03.007

255. Kiani S, Akhavan-Niaki H, Fattahi S, et al. Purified sulforaphane from broccoli (*Brassica oleracea* var *Italica*) leads to alterations of CDX1 and CDX2 expression and changes in Mir-9 and Mir-326 levels in human gastric cancer cells. *Gene*. 2018;678:115–123.
256. Larki P, Ahadi A. Up-regulation of miR-21, miR-25, miR-93, and miR-106b in gastric cancer. *Iran Biomed J*. 2018;22(6):367–373. doi:10.29252/22.6.367
257. Amiri RM, Tehrani M, Taghizadeh S, Shokri-Shirvani J, Fakhri H, Ajami A. Association of nucleotide-binding oligomerization domain receptors with peptic ulcer and gastric cancer. *Iran J Allergy Asthma Immunol*. 2016;15(5):355–362.
258. Mirmajidi SH, Najafi M, Mirmajidi ST, Nasrabadi NN. Study of regulatory promoter polymorphism (-248 G> A) of Bax gene in patients with gastric cancer in the northern provinces of Iran. *Gastroenterol Hepatol Bed Bench*. 2016;9(1):36–44.
259. Kordi-Tamandani DM, Davani SK, Baranzehi T, Hemati S. Analysis of promoter methylation, polymorphism and expression profile of cytotoxic T-lymphocyte-associated antigen-4 in patients with gastric cancer. *J Gastrointestina Liver Dis*. 2014;23(3):249–253. doi:10.15403/jgld.2014.1121.233.dmk

Clinical and Experimental Gastroenterology

Dovepress

Publish your work in this journal

Clinical and Experimental Gastroenterology is an international, peer-reviewed, open access, online journal publishing original research, reports, editorials, reviews and commentaries on all aspects of gastroenterology in the clinic and laboratory. This journal is indexed on American Chemical Society's Chemical Abstracts Service (CAS).

The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/clinical-and-experimental-gastroenterology-journal>